U.S. patent application number 11/963109 was filed with the patent office on 2008-07-03 for electroprocessing in drug delivery and cell encapsulation.
This patent application is currently assigned to Virginia Commonwealth University Intellectual Property Foundation. Invention is credited to Gary L. Bowlin, David G. Simpson, Gary E. Wnek.
Application Number | 20080159985 11/963109 |
Document ID | / |
Family ID | 27399425 |
Filed Date | 2008-07-03 |
United States Patent
Application |
20080159985 |
Kind Code |
A1 |
Bowlin; Gary L. ; et
al. |
July 3, 2008 |
Electroprocessing in drug delivery and cell encapsulation
Abstract
The invention is directed to novel compositions comprising an
electroprocessed material and a substance, their formation and use.
The electroprocessed material can, for example, be one or more
natural materials, one or more synthetic materials, or a
combination thereof. The substance can be one or more therapeutic
or cosmetic substances or other compounds, molecules, cells,
vesicles. The compositions can be used in substance delivery,
including drug delivery within an organism by, for example,
releasing substances or containing cells that release substances.
The compositions can be used for other purposes, such as prostheses
or similar implants.
Inventors: |
Bowlin; Gary L.;
(Mechanicsville, VA) ; Wnek; Gary E.; (Cleveland,
OH) ; Simpson; David G.; (Mechanicsville,
VA) |
Correspondence
Address: |
FOLEY HOAG, LLP;PATENT GROUP, WORLD TRADE CENTER WEST
155 SEAPORT BLVD
BOSTON
MA
02110
US
|
Assignee: |
Virginia Commonwealth University
Intellectual Property Foundation
Richmond
VA
|
Family ID: |
27399425 |
Appl. No.: |
11/963109 |
Filed: |
December 21, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10668085 |
Sep 22, 2003 |
7374774 |
|
|
11963109 |
|
|
|
|
09982515 |
Oct 18, 2001 |
|
|
|
10668085 |
|
|
|
|
09946158 |
Sep 4, 2001 |
|
|
|
09982515 |
|
|
|
|
09654517 |
Sep 1, 2000 |
|
|
|
09946158 |
|
|
|
|
09714255 |
Nov 17, 2000 |
|
|
|
09982515 |
|
|
|
|
09512081 |
Feb 24, 2000 |
|
|
|
09714255 |
|
|
|
|
09386273 |
Aug 31, 1999 |
6592623 |
|
|
09512081 |
|
|
|
|
09512081 |
Feb 24, 2000 |
|
|
|
09982515 |
|
|
|
|
09386273 |
Aug 31, 1999 |
6592623 |
|
|
09512081 |
|
|
|
|
09386273 |
Aug 31, 1999 |
6592623 |
|
|
09982515 |
|
|
|
|
60241008 |
Oct 18, 2000 |
|
|
|
60270118 |
Feb 22, 2001 |
|
|
|
Current U.S.
Class: |
424/93.1 ;
435/325; 514/13.6; 514/14.7; 514/20.9; 514/23; 514/44R; 514/54 |
Current CPC
Class: |
Y10S 514/801 20130101;
A61L 27/18 20130101; A61L 31/041 20130101; A61L 31/041 20130101;
B29C 67/0007 20130101; A61P 17/00 20180101; A61L 27/507 20130101;
C08L 67/04 20130101; A61L 27/34 20130101; C08L 89/00 20130101; C08L
89/06 20130101; C08L 89/00 20130101; A61L 27/225 20130101; C12N
5/0012 20130101; A61K 2035/126 20130101; C12N 2533/54 20130101;
A61L 15/32 20130101; A61L 27/26 20130101; C12N 5/0062 20130101;
A61P 19/08 20180101; A61F 2/08 20130101; A61L 27/34 20130101; A61L
2400/04 20130101; A61P 31/00 20180101; C12N 2503/00 20130101; A61K
35/12 20130101; C12N 2510/00 20130101; C12N 5/0068 20130101; B29C
41/006 20130101; C12N 5/0622 20130101; A61L 27/24 20130101; A61L
27/26 20130101; A61L 27/3847 20130101; C07K 14/75 20130101; A61L
27/38 20130101; C12N 2533/40 20130101; A61P 3/10 20180101; C12N
2533/56 20130101; A61L 27/18 20130101; C07K 14/78 20130101; A61L
2430/30 20130101 |
Class at
Publication: |
424/93.1 ;
435/325; 514/2; 514/44; 514/23; 514/8; 514/54 |
International
Class: |
A61K 35/00 20060101
A61K035/00; C12N 5/06 20060101 C12N005/06; A61K 38/02 20060101
A61K038/02; A61K 31/7052 20060101 A61K031/7052; A61K 31/70 20060101
A61K031/70; A61K 38/14 20060101 A61K038/14; A61K 31/726 20060101
A61K031/726 |
Claims
1. A composition comprising: an electroprocessed material and a
substance.
2. The composition of claim 1, wherein the material is one or more
natural materials, one or more synthetic materials, or a
combination thereof.
3. The composition of claim 1, wherein the material is a
combination of one or more natural materials and one or more
synthetic materials.
4. The composition of claim 2, wherein the natural material
comprises one or more amino acids, peptides, denatured peptides,
polypeptides, proteins, carbohydrates, lipids, nucleic acids,
glycoproteins, lipoproteins, glycolipids, glycosaminoglycans,
proteoglycans, or a combination thereof.
5. The composition of claim 2, wherein the synthetic material
comprises one or more polymers.
6. The composition of claim 1, wherein the substance comprises a
therapeutic substance, a cosmetic substance or a combination
thereof
7. The composition of claim 1, wherein the substance comprises one
or more molecules, cells, objects, or combinations thereof.
8. The composition of claim 1, further comprising placement of the
composition in a bioreactor.
9. The composition of claim 1, wherein the electroprocessed
material is crosslinked.
10. A composition comprising an electroprocessed material, wherein
the electroprocessed material provides a biological effect when
delivered to a desired location in vivo or in vitro.
11. A method of delivering a substance to a desired location,
comprising placing the composition of claim 1 at the desired
location.
12. A method of delivering an electroprocessed material to a
desired location, comprising placing the composition of claim 10 at
the desired location.
13. The method of claim 11, wherein the substance comprises a
molecule or a cell that will release the molecule after placement
in the desired location.
14. The method of claim 11, wherein the substance comprises a
therapeutic substance, a cosmetic substance or a combination
thereof.
15. The method of claim 11, wherein the substance comprises one or
more molecules, cells, objects, or combinations thereof.
16. The method of claim 11, wherein the substance comprises a
cell.
17. The method of claim 11, wherein the location is inside or upon
the body of a human or an animal.
18. A method of manufacturing the composition of claim 1,
comprising: electrodepositing one or more electrically-charged
solutions comprising a material or molecules capable of forming the
material onto a grounded substrate under conditions effective to
electrodeposit the material or the molecules capable of forming the
material on the substrate to form the electroprocessed material;
and, adding the substance to the electrodeposited material to form
the composition.
19. The method of claim 18, wherein the material is one or more
natural materials, one or more synthetic materials, or a
combination thereof
20. The method of claim 18, wherein the substance comprises a
therapeutic substance, a cosmetic substance or a combination
thereof.
21. The method of claim 18, wherein the substance comprises one or
more molecules, cells, objects, or combinations thereof.
22. A method of manufacturing the composition of claim 10,
comprising electrodepositing one or more electrically-charged
solutions comprising a material or molecules capable of forming the
material onto a grounded substrate under conditions effective to
electrodeposit the material or the molecules capable of forming the
material on the substrate to form the electroprocessed
material.
23. The method of claim 22, wherein the material is one or more
natural materials, one or more synthetic materials, or a
combination thereof.
Description
PRIOR RELATED APPLICATIONS
[0001] This application claims priority to U.S. provisional patent
application Ser. No. 60/241,008 filed Oct. 18, 2000, U.S.
provisional patent application Ser. No. 60/270,118 filed Feb. 22,
2001, U.S. non-provisional patent application Ser. No. 09/714,255
filed Nov. 17, 2000, and U.S. non-provisional patent application
Ser. No. 09/946,158 filed Sep. 4, 2001.
FIELD OF THE INVENTION
[0002] The present invention relates to novel compositions
comprising electroprocessed materials with substances, and methods
of making and using these compositions in delivery of
substances.
BACKGROUND OF THE INVENTION
[0003] Numerous methods exist for delivering substances to desired
locations in vivo or in vitro. One such method uses devices or
objects that contain a substance and will release the substance
within a desired location. One desirable application for such
methods is the administration of such objects to a location within
the body of an organism, followed by the subsequent release of the
desired substance into the body. In these examples, the implant
often contains the substance and a carrier. After implantation, the
substance is released by a variety of means including, for example,
diffusion from an implant or dissolution or other degradation of a
capsule coat.
[0004] Biocompatibility is a desirable attribute in compositions
designed for substance delivery. With surgical and subdermal
implants, for example, the substance to be delivered is often
contained in a matrix comprised of synthetic polymers. Where
natural products are used in making bandages, the products
typically comprise wood products such as cellulose or other
materials that are not readily absorbed by the body of the
recipient. Accordingly, such bandages must eventually be removed.
Implants compressed from natural materials that may be absorbed by
the body are one way to improve biocompatibility and is one area in
which improvements are desired.
[0005] There is also a continuing need for greater versatility and
flexibility in substance delivery technology. Additional techniques
for controlling release kinetics and spatial patterns of release or
delivery are examples of developments that can improve substance
delivery. Implants in which there is refined control of structure
at the microscopic or molecular level and overall implant shape are
also desired. Such methods could allow, for example, further
refinements in control of pore size or other attributes that affect
diffusion in and out of a matrix, or more refined control of the
distribution of a substance within a matrix. New methods that allow
encapsulation of living cells within a matrix are especially
desired. Such methods would allow implants to contain, for example,
cells that produced desired substances, cells that promote tissue
growth, or cells that serve both of these functions.
[0006] What is needed therefore are new compositions for use in
drug delivery that provide additional and improved methods of
controlling configuration of drug delivery systems. Compositions
with improved biocompatibility compared to those currently used in
substance delivery and/or that can contain living cells are also
needed. What is further needed are new methods of substance
delivery using such compositions. Finally, methods for making such
compositions are also needed.
SUMMARY OF THE INVENTION
[0007] The present invention seeks to overcome the limitations in
the prior art by providing compositions comprising an
electroprocessed material and a substance. The substance may be the
material itself, or another substance which may be delivered with
the electroprocessed material to a desired site. Sometimes the
compositions comprising an electroprocessed material and a
substance are in the form of a matrix. The electroprocessed
materials include any natural or non-natural materials or blends
thereof. The substance is released from the composition or causes
the release of molecules or compounds from the composition.
Substance release can occur in vitro, in vivo, or both.
[0008] The present invention also includes a method for delivery of
substances to a location using the present compositions comprising
an electroprocessed material and a substance. The locations can be
in vitro, in vivo, or both. The invention also includes methods for
making the compositions of the present invention.
[0009] The compositions of the present invention include an
electroprocessed material and a substance. The material can include
naturally occurring materials, synthetically manufactured
materials, or combinations thereof. Naturally occurring materials
include natural organic or inorganic materials, genetically
engineered materials and include synthetic alterations thereof.
Synthetic materials include materials prepared through any method
of artificial synthesis, processing, or manufacture. The invention
includes materials that degrade and can absorbed by the body, or
will persist in whole or in part and become portions of an
extracellular tissue matrix. The compositions may be made using any
electroprocessing technique, including but not limited to
electrospinning, electroaerosol, electrospraying or
electrosputtering techniques, or any combination thereof.
Accordingly, electroprocessed droplets, particles, fibers, fibrils,
or combinations thereof are all included in the compositions of the
present invention. In a preferred embodiment, the electroprocessed
materials form a matrix, and in some cases are similar to an
extracellular matrix. Matrices may also be formed from materials
that can combine to form another material, such as precursor
materials. For example, fibrinogen, when combined with thrombin,
will form fibrin.
[0010] Any material that may be electroprocessed may be used to
form an electroprocessed material to be combined, either before,
during or after electroprocessing, with a substance, to form the
compositions of the present invention. The compositions of the
present invention contain one or more substances. The substance
includes any type of substance desired, with examples including
molecules, cells, objects, or combinations thereof. In some cases,
the substance is the electroprocessed material itself. Molecules
can be any size, complexity, or type, including both organic or
inorganic molecules as well as any combination of molecules.
Molecules include naturally occurring and synthetic molecules.
Examples of molecules include, but are not limited to therapeutics,
cosmetics, nutraceuticals, vitamins, minerals, humectants,
molecules produced by cells, including normal cells, abnormal
cells, genetically engineered cells and cells modified through any
other process. Both eukaryotic and prokaryotic cells are included
in the category of substances. Substances also include, without
limitation, antigens, antimicrobials, antifungals, molecules that
can cause a cellular or physiological response, metals, gases,
minerals, ions, and electrically, magnetically and
electromagnetically (i.e., light) reactive materials. Cells are
derived from natural sources or are cultured in vitro. Combinations
of different types or categories of cells can be used. Examples of
objects include, but are not limited to, cell fragments, cell
debris, organelles and other cellular components, tablets, viruses,
vesicles, liposomes, capsules, and other structures that serve as
an enclosure for molecules. It is to be understood that the
composition of the present invention comprises at least one
substance. Accordingly, numerous substances or combinations of
similar or different substances may be combined with the
electroprocessed material. The substances may be combined with the
electroprocessed material through electroprocessing techniques or
through other techniques. The invention also includes embodiments
in which the composition comprises electroprocessed matrix
materials without an additional substance. In that embodiment, the
electroprocessed matrix materials may act as a substance.
[0011] The invention provides numerous uses for the compositions of
the present invention. One preferred use is the delivery of
substances. Substance delivery from the compositions of the present
invention can occur in vivo, for example upon or within the body of
a human or animal. Substance delivery can also occur in vitro, for
example within a cell culture apparatus or well. Substances
delivered include those substances contained within the
compositions, other substances produced by the substance contained
in the composition, or both. For example, a substance may be a cell
contained within the electroprocessed material, and the cell may
synthesize and release one or more molecules. Cells may release
molecules in response to signals, so that the molecules are
released in a specific desired circumstance. For example, an
inducible promoter in an engineered cell within an electroprocessed
material may be used to stimulate the expression and or release of
a growth factor.
[0012] The compositions of the present invention are versatile with
respect to control of substance release from the compositions.
Release kinetics of substances can be controlled by manipulating a
wide variety of matrix parameters. In various embodiments, the
release rate, onset of release, release of more than one compound
either at the same or different times, creation of gradients of
release and spatial patterns of release may be manipulated.
Compositions that contain electrical or magnetic materials can be
influenced to move, cause motion, or produce a biological activity
by applying an electric current or a magnetic field to the
composition located on or within a body, or in vitro.
Electroprocessed compositions that contain light sensitive
components may be designed. These compositions may move or be
induced to release or bind substances in response to specific
wavelengths of light. Compositions containing nucleic acids or
genetically engineered cells, for example, can be used in gene
therapy. Other examples include embodiments used in wound care,
tissue or organ replacements, and prostheses. In some embodiments,
the electroprocessed material itself contains desired properties of
substances, and acts as a substance without addition of another
substance. The invention thus includes a wide variety of methods of
using the compositions of the present invention in medical
veterinary, agricultural, research and other applications. The
compositions of the present invention provide safer and more
predictable release of substances and provide a major advance in
the field of substance delivery, especially drug delivery.
[0013] The invention also includes methods for making the
compositions of the present invention using any type of
electroprocessing technique, combination of electroprocessing
techniques, or a combination of an electroprocessing technique and
another technique, such as aerosol techniques. The method includes
streaming, spraying, dropping or projecting one or more solutions,
fibers, or suspensions comprising the materials to be
electroprocessed toward a target under conditions effective to
deposit the materials on a substrate. The substances to be combined
with the electroprocessed materials may be electroprocessed toward
the target either before, during or after electroprocessing the
material. In this manner, the substance may be incorporated within
the electroprocessed material during formation, or may coat the
electroprocessed material. Accordingly, one or a plurality of
sources of materials and substances is used to provide the
ingredients for the electroprocessed composition of the present
invention. For example, collagen and a polymer such as poly
glycolic acid may be electroprocessed through any combination of
electrospinning and electrospraying from two sources. At the same
time or at selected times thereafter, substances may be provided
from other sources: for example, a third source provides a growth
factor, a fourth source provides an anti-angiogenic factor, and a
fifth source provides genetically altered fibroblasts. These
sources of substances may provide the substances through one or
more electroprocessing techniques, such as electrospin,
electrospray, electroaerosol, electrosputter or any combination
thereof. These sources may also provide the substances to the
electroprocessed material through non-electroprocessing techniques,
such as aerosol delivery, dripping, coating, soaking or other
techniques.
[0014] In one preferred embodiment, the compositions of the present
invention comprise one or more electroprocessed materials that form
a matrix combined with at least one substance. Either the source or
target is charged, and the other is grounded. The substrate upon
which electrodeposition occurs can be the target itself or another
object of any shape or type. For example, the substrate can be an
object disposed between the orifice and the target. In one
embodiment, the substrate is a location on or within an organism,
such as a tissue, a wound site, a desired location for substance
delivery, or a surgical field in which the composition is to be
applied. By manipulating process parameters, compositions of the
present invention can be manufactured with a predetermined shape,
for example, for depositing the material onto or into a molded
substrate. Substrate shape can be manipulated to achieve a specific
three-dimensional structure. Targets can also be rotated or
otherwise moved or manipulated during electroprocessing to control
distribution of the electroprocessed material and, in embodiments
involving electroprocessed fibers, the orientation of the fibers.
Substances included in the composition can be combined with the
matrix material by any means before, during, and/or after
electrodeposition.
[0015] The electroprocessed compositions may be formed into any
desired shape. For purposes of substance delivery, the desired
shape is dictated by the application. Non-limiting examples include
the following: in the form of a patch for application to the skin;
in the form of a wafer or tablet for ingestion; in the form of a
wafer for application to a site of removal of a glioma; in the form
of a wrap to surround a tumor; in a particulate form for spraying
on a surgical site; and in a particulate form for delivery of
substances through inhalation.
[0016] Accordingly, it is an object of the present invention to
overcome the foregoing limitations and drawbacks by providing
compositions comprising an electroprocessed material and a
substance.
[0017] Another object of the present invention is to provide
compositions comprising an electroprocessed natural material and a
substance.
[0018] Yet another object of the present invention is to provide
compositions comprising an electroprocessed synthetic material and
a substance.
[0019] Still another object of the present invention is to provide
compositions comprising blends of an electroprocessed natural
material, an electroprocessed synthetic material and a
substance.
[0020] Another object of the present invention is to provide
compositions comprising an electroprocessed synthetic material and
a substance.
[0021] It is an object of the present invention to provide
compositions comprising an electroprocessed material and a
substance, wherein the substances comprises comprising cells.
[0022] Another object of the present invention is to provide
compositions comprising an electroprocessed material and a
substance, wherein the substance comprises an object.
[0023] Still another object of the present invention is to provide
compositions comprising an electroprocessed material and a
substance, wherein the substance comprises a molecule.
[0024] Yet another object of the present invention is to provide
compositions comprising an electroprocessed material and a
substance, wherein the substance comprises a therapeutic
molecule.
[0025] Another object of the present invention is to provide
compositions comprising an electroprocessed material and substances
comprising combinations of cells, molecules, and/or objects.
[0026] Another object of the present invention is to provide
methods for delivery of a substance to a location, comprising
placing the composition of the present invention at a desired
location.
[0027] Still another object of the present invention is to provide
methods for delivery of substances to a location inside or upon the
body of a human or animal.
[0028] Yet another object of the present invention is to provide
methods for retrieval of substances from a location inside or upon
the body of a human or animal by bonding such substances.
[0029] Yet another object of the present invention is to provide
methods for delivery or retrieval of substances to in vitro
locations.
[0030] Another object of the present invention is to provide
methods for delivery of drugs in vivo.
[0031] Yet another object of the present invention is to provide
methods of administering gene and or peptide therapy.
[0032] Another object of the present invention is to provide
methods of protein or peptide therapy.
[0033] Still another object of the present invention is to provide
methods of administering tissue and organ replacements and
prostheses.
[0034] Another object of the present invention is to provide
methods for making the compositions of the present inventions.
[0035] These and other objects, features and advantages of the
present invention will become apparent after a review of the
following detailed description of the disclosed embodiments and the
appended drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0036] FIG. 1 is a schematic drawing of an embodiment of an
electroprocessing device including the electroprocessing equipment
and a rotating wall bioreactor.
[0037] FIG. 2 is a schematic drawing of an embodiment of an
electroprocessing device including the electroprocessing equipment
and a rotating wall bioreactor.
[0038] FIG. 3 is a graph showing the release profile of vascular
endothelial growth factor (VEGF) from one embodiment of the present
invention obtained by electrospinning a solution comprising
collagen, polylactic acid (PLA), polyglycolic acid (PGA), and
VEGF.
[0039] FIG. 4 is a graph showing the release profile of VEGF from
an embodiment of the present invention obtained by electrospinning
a solution comprising collagen, polylactic acid, and polyglycolic
acid, and VEGF and subsequently cross-linking the electroprocessed
material by exposure to glutaraldehyde vapor.
[0040] FIG. 5 is a graph showing the release profile of
tetracycline from several embodiments of the present invention
obtained by electrospinning solutions containing tetracycline along
with PLA, poly(ethylene-co-vinyl acetate) or a combination of PLA
and poly(ethylene-co-vinyl acetate).
[0041] FIG. 6 is a graph comparing the release profile of
tetracycline from an embodiment of the present invention and
several other compositions. The embodiment of the present invention
was obtained by electrospinning a solution containing tetracycline
with poly(ethylene-co-vinyl acetate). The other compositions were
periodontal fibers containing 25 wt % tetracycline hydrochloride
and films containing tetracycline with polylactic acid,
poly(ethylene-co-vinyl acetate) or a combination of polylactic acid
and poly(ethylene-co-vinyl acetate).
[0042] FIG. 7 is a graph showing the release profile of
tetracycline from several embodiments of the present invention
obtained by electrospinning solutions containing tetracycline with
poly(ethylene-co-vinyl acetate).
[0043] FIG. 8 is a schematic drawing of another embodiment of an
electroprocessing device including the electroprocessing equipment
and a rotating wall bioreactor.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0044] The term "substance" shall be used throughout this
application in its broadest definition. The term substance includes
one or more molecules, objects, or cells of any type or size, or
combinations thereof. Substances can be in any form including, but
not limited to solid, semisolid, wet or dry mixture, gas, solution,
suspension, combinations thereof. Substances include molecules of
any size and in any combination. Cells include all cell types of
prokaryotic and eukaryotic cells, whether in natural state or
altered by genetic engineering or any other process. Cells can be
from a natural source or cultured in vitro and can be living or
dead. Combinations of different types of cells can be used. Objects
can be of any size, shape, and composition that may be combined
with or coupled to an electroprocessed material. Examples of
objects include, but are not limited to, cell fragments, cell
debris, fragments of cell walls, fragments of viral walls,
organelles and other cell components, tablets, viruses, vesicles,
liposomes, capsules, nanoparticulates, and other structures that
serve as an enclosure for molecules. The compositions of the
present invention may comprise one substance or any combination of
substances.
[0045] The terms "electroprocessing" and "electrodeposition" shall
be defined broadly to include all methods of electrospinning,
electrospraying, electroaerosoling, and electrosputtering of
materials, combinations of two or more such methods, and any other
method wherein materials are streamed, sprayed, sputtered or
dripped across an electric field and toward a target. The
electroprocessed material can be electroprocessed from one or more
grounded reservoirs in the direction of a charged substrate or from
charged reservoirs toward a grounded target. "Electrospinning"
means a process in which fibers are formed from a solution or melt
by streaming an electrically charged solution or melt through an
orifice. "Electroaerosoling" means a process in which droplets are
formed from a solution or melt by streaming an electrically charged
polymer solution or melt through an orifice. The term
electroprocessing is not limited to the specific examples set forth
herein, and it includes any means of using an electrical field for
depositing a material on a target.
[0046] The term "material" refers to any compound, molecule,
substance, or group or combination thereof that forms any type of
structure or group of structures during or after electroprocessing.
Materials include natural materials, synthetic materials, or
combinations thereof. Naturally occurring organic materials include
any substances naturally found in the body of plants or other
organisms, regardless of whether those materials have or can be
produced or altered synthetically. Synthetic materials include any
materials prepared through any method of artificial synthesis,
processing, or manufacture. Preferably the materials are
biologically compatible materials.
[0047] One class of synthetic materials, preferably biologically
compatible synthetic materials, comprises polymers. Such polymers
include but are not limited to the following: poly(urethanes),
poly(siloxanes) or silicones, poly(ethylene), poly(vinyl
pyrrolidone), poly(2-hydroxy ethyl methacrylate), poly(N-vinyl
pyrrolidone), poly(methyl methacrylate), poly(vinyl alcohol),
poly(acrylic acid), polyacrylamide, poly(ethylene-co-vinyl
acetate), poly(ethylene glycol), poly(methacrylic acid),
polylactides (PLA), polyglycolides (PGA),
poly(lactide-co-glycolides) (PLGA), polyanhydrides, and
polyorthoesters or any other similar synthetic polymers that may be
developed that are biologically compatible. The term "biologically
compatible, synthetic polymers" shall also include copolymers and
blends, and any other combinations of the forgoing either together
or with other polymers generally. The use of these polymers will
depend on given applications and specifications required. A more
detailed discussion of these polymers and types of polymers is set
forth in Brannon-Peppas, Lisa, "Polymers in Controlled Drug
Delivery," Medical Plastics and Biomaterials, November 1997, which
is incorporated by reference as if set forth fully herein.
[0048] "Materials" also include electroprocessed materials that are
capable of changing into different materials during or after
electroprocessing. For example, the protein fibrinogen, when
combined with thrombin, forms fibrin. Fibrinogen or thrombin that
are electroprocessed as well as the fibrin that later forms are
included within the definition of materials. Similarly, procollagen
will form collagen when combined with procollagen peptidase.
Procollagen, procollagen peptidase, and collagen are all within the
definition.
[0049] In a preferred embodiment, the electroprocessed materials
form a matrix. The term "matrix" refers to any structure comprised
of electroprocessed materials. Matrices are comprised of fibers, or
droplets of materials, or blends of fibers and droplets of any size
or shape. Matrices are single structures or groups of structures
and can be formed through one or more electroprocessing methods
using one or more materials. Matrices are engineered to possess
specific porosities. Substances may be deposited within, or
anchored to or placed on matrices. Cells are substances which may
be deposited within or on matrices.
[0050] One preferred class of materials for electroprocessing to
make the compositions of the present invention comprises proteins.
Extracellular matrix proteins are a preferred class of proteins in
the present invention. Examples include but are not limited to
collagen, fibrin, elastin, laminin, and fibronectin. Additional
preferred materials are other components of the extracellular
matrix, for example proteoglycans. In each case, those names are
used throughout the present application in their broadest
definition. There are multiple types of each of these proteins that
are naturally-occurring as well as types that can be or are
synthetically manufactured or produced by genetic engineering. For
example, collagen occurs in many forms and types. All of these
types and subsets are encompassed in the use of the proteins named
herein. The term protein further includes, but is not limited to,
fragments, analogs, conservative amino acid substitutions, and
substitutions with non-naturally occurring amino acids with respect
to each named protein. The term "residue" is used herein to refer
to an amino acid (D or L) or an amino acid mimetic that is
incorporated into a protein by an amide bond. As such, the amino
acid may be a naturally occurring amino acid or, unless otherwise
limited, may encompass known analogs of natural amino acids that
function in a manner similar to the naturally occurring amino acids
(i.e., amino acid mimetics). Moreover, an amide bond mimetic
includes peptide backbone modifications well known to those skilled
in the art.
[0051] Furthermore, one of skill will recognize that, as mentioned
above, individual substitutions, deletions or additions which
alter, add or delete a single amino acid or a small percentage of
amino acids (typically less than 5%, more typically less than 1%)
in an encoded sequence are conservatively modified variations where
the alterations result in the substitution of an amino acid with a
chemically similar amino acid. Conservative substitution tables
providing functionally similar amino acids are well known in the
art. The following six groups each contain amino acids that are
conservative substitutions for one another:
1) Alanine (A), Serine (S), Threonine (T);
[0052] 2) Aspartic acid (D), Glutamic acid (E);
3) Asparagine (N), Glutamine (Q);
4) Arginine (R), Lysine (K);
5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).
[0053] It is to be understood that the term protein, polypeptide or
peptide further includes fragments that may be 90 to 95% of the
entire amino acid sequence, and also extensions to the entire amino
acid sequence that are 5% to 10% longer than the amino acid
sequence of the protein, polypeptide or peptide.
[0054] When peptides are relatively short in length (i.e., less
than about 50 amino acids), they are often synthesized using
standard chemical peptide synthesis techniques. Solid phase
synthesis in which the C terminal amino acid of the sequence is
attached to an insoluble support followed by sequential addition of
the remaining amino acids in the sequence is a preferred method for
the chemical synthesis of the antigenic epitopes described herein.
Techniques for solid phase synthesis are known to those skilled in
the art.
[0055] Alternatively, the proteins or peptides that may be
electroprocessed are synthesized using recombinant nucleic acid
methodology. Generally, this involves creating a nucleic acid
sequence that encodes the peptide or protein, placing the nucleic
acid in an expression cassette under the control of a particular
promoter, expressing the peptide or protein in a host, isolating
the expressed peptide or protein and, if required, renaturing the
peptide or protein. Techniques sufficient to guide one of skill
through such procedures are found in the literature.
[0056] When several desired protein fragments or peptides are
encoded in the nucleotide sequence incorporated into a vector, one
of skill in the art will appreciate that the protein fragments or
peptides may be separated by a spacer molecule such as, for
example, a peptide, consisting of one or more amino acids.
Generally, the spacer will have no specific biological activity
other than to join the desired protein fragments or peptides
together, or to preserve some minimum distance or other spatial
relationship between them. However, the constituent amino acids of
the spacer may be selected to influence some property of the
molecule such as the folding, net charge, or hydrophobicity.
Nucleotide sequences encoding for the production of residues which
may be useful in purification of the expressed recombinant protein
may be built into the vector. Such sequences are known in the art.
For example, a nucleotide sequence encoding for a poly histidine
sequence may be added to a vector to facilitate purification of the
expressed recombinant protein on a nickel column.
[0057] Once expressed, recombinant peptides, polypeptides and
proteins can be purified according to standard procedures known to
one of ordinary skill in the art, including ammonium sulfate
precipitation, affinity columns, column chromatography, gel
electrophoresis and the like. Substantially pure compositions of
about 50 to 99% homogeneity are preferred, and 80 to 95% or greater
homogeneity are most preferred for use as therapeutic agents.
[0058] Also, molecules capable of forming some of the named
proteins can be mixed with other polymers during electroprocessing
to obtain desired properties for uses of the formed protein in the
matrix.
[0059] Throughout this application the term "solution" is used to
describe the liquid in the reservoirs of the electroprocessing
method. The term is defined broadly to include any liquids that
contain materials to be electroprocessed. It is to be understood
that any solutions capable of forming a material during
electroprocessing are included within the scope of the present
invention. In this application, the term "solution" also refers to
suspensions or emulsions containing the material or anything to be
electrodeposited. "Solutions" can be in organic or biologically
compatible forms. This broad definition is appropriate in view of
the large number of solvents or other liquids and carrier
molecules, such as polyethylene glycol (PEG), that can be used in
the many variations of electroprocessing. In this application, the
term "solution" also refers to melts, hydrated gels and suspensions
containing the materials, substances or anything to be
electrodeposited.
Solvents
[0060] Any solvent that will allows delivery of the material or
substance to the orifice or tip of a syringe under such conditions
that the material or substance will be processed as desired may be
used for dissolving or suspending the material or the substance to
be electroprocessed. Solvents useful for dissolving or suspending a
material or a substance will depend on the material or substance.
Electrospinning techniques often require more specific solvent
conditions. For example, non cross-linked fibrin monomer can be
electrodeposited or electrospun from solvents such as urea,
monochloroacetic acid, water, 2,2,2-trifluoroethanol, or
1,1,1,3,3,3-hexafluoro-2-propanol (also known as
hexafluoroisopropanol or HFIP). Collagen can be electrodeposited as
a solution or suspension in water, 2,2,2-trifluoroethanol, or HFIP.
Elastin can be electrodeposited as a solution or suspension in
water, 2,2,2-trifluoroethanol, isopropanol, or HFIP. Other lower
order alcohols, especially halogenated alcohols, may be used.
Proteins and peptides associated with membranes are often
hydrophobic and thus cannot dissolve in aqueous solutions. Such
proteins can be dissolved in organic solvents such as methanol,
chloroform, and trifluoroethanol (TFE). Any other solvents known to
one of skill in the protein chemical art may be used, for example
solvents useful in chromatography, especially high performance
liquid chromatography. Proteins and peptides are also soluble, for
example, in HFIP, hexafluoroacetone, chloroalcohols in conjugation
with aqueous solutions of mineral acids, dimethylacetamide
containing 5% lithium chloride, in very dilute acids such as acetic
acid and formic acid. N-methyl morpholine-N-oxide is another
solvent that can be used with many polypeptides.
[0061] In functional terms, solvents used for electroprocessing
have the principal role of creating a mixture with a polymer, or
polymers, such that electroprocessing is feasible. The
concentration of a given solvent is often an important
consideration in determining the type of electroprocessing that
will occur. For example, in electrospraying, the solvent should
assist in the dispersion of droplets of electroprocessed material
so that the initial jet of liquid disintegrates into droplets.
Accordingly, solvents used in electrospraying should not create
forces that will stabilize an unconfined liquid column. In
electrospinning, interactions between molecules of electroprocessed
material stabilize the jet, leading to fiber formation.
Accordingly, for electrospun embodiments, the solvent should
sufficiently dissolve or disperse the polymer to prevent the jet
from disintegrating into droplets and should thereby allow
formation of a stable jet in the form of a fiber. In some
embodiments, the transition from electrospraying to electrospinning
can be determined by examining Brookfield viscosity measurements
for polymer solutions as a function of concentration. Brookfield
viscosity increases as concentration of a polymer or other material
to be electroprocessed increases. Above a critical concentration
associated with extensive chain entanglements of materials,
however, the Brookfield viscosity will increase more rapidly with
concentration, as opposed to a more gradual, linear rise with
concentration at lower concentrations. For example, the Brookfield
viscosity of a poly(lactide) sample obtained from Alkermes
dissolved in chloroform shows an upturn in the Brookfield
viscosity/concentration plot at approximately 7-8% w/v. A sample of
poly(ethylene-co-vinyl acetate) from Dupont (ELVAX 40W) shows an
upturn at 14-15% w/v. In both cases, these departures from
linearity approximately coincide with the transition from
electrospraying to electrospinning.
Compositions of the Present Invention
[0062] The Electroprocessed Material
[0063] One component of the compositions of the present invention
is the electroprocessed material. As defined above, the
electroprocessed material of the present invention can include
natural materials, synthetic materials, or combinations thereof.
Examples include but are not limited to amino acids, peptides,
denatured peptides such as gelatin from denatured collagen,
polypeptides, proteins, carbohydrates, lipids, nucleic acids,
glycoproteins, lipoproteins, glycolipids, glycosaminoglycans, and
proteoglycans.
[0064] Some preferred materials are naturally occurring
extracellular matrix materials and blends of naturally occurring
extracellular matrix materials, including but not limited to
collagen, fibrin, elastin, laminin, fibronectin, hyaluronic acid,
chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate,
heparin sulfate, heparin, and keratan sulfate, and proteoglycans.
These materials may be isolated from humans or other animals or
cells or synthetically manufactured. Some especially preferred
natural matrix materials are collagen and fibrin and fibronectin.
Also included are crude extracts of tissue, extracellular matrix
material, extracts of nonnatural tissue, or extracellular matrix
materials (i.e. extracts of cancerous tissue), alone or in
combination. Extracts of biological materials, including but not
limited to cells, tissues, organs, and tumors may also be
electroprocessed. Collagen has been electrospun to produce a
repeating, banded pattern observed with electron microscopy. This
banded pattern is typical of collagen fibrils produced by natural
processes (i.e. banded pattern is observed in collagen when it is
produced by cells). In some embodiments, collagen is electrospun
such that it has a 65 nm banding pattern.
[0065] It is to be understood that these electroprocessed materials
may be combined with other materials and/or substances in forming
the compositions of the present invention. For example, an
electroprocessed peptide may be combined with an adjuvant to
enhance immunogenicity when implanted subcutaneously. As another
example, an electroprocessed collagen matrix, containing cells, may
be combined with an electroprocessed biologically compatible
polymer and growth factors to stimulate growth and division of the
cells in the collagen matrix.
[0066] Synthetic materials include any materials prepared through
any method of artificial synthesis, processing, or manufacture. The
synthetic materials are preferably biologically compatible for
administration in vivo or in vivo. Such polymers include but are
not limited to the following: poly(urethanes), poly(siloxanes) or
silicones, poly(ethylene), poly(vinyl pyrrolidone), poly(2-hydroxy
ethyl methacrylate), poly(N-vinyl pyrrolidone), poly(methyl
methacrylate), poly(vinyl alcohol), poly(acrylic acid),
polyacrylamide, poly(ethylene-co-vinyl acetate), poly(ethylene
glycol), poly(methacrylic acid), polylactic acid (PLA),
polyglycolic acids (PGA), poly(lactide-co-glycolides) (PLGA),
nylons, polyamides, polyanhydrides, poly(ethylene-co-vinyl alcohol)
(EVOH), polycaprolactone, poly(vinyl acetate) (PVA),
polyvinylhydroxide, poly(ethylene oxide) (PEO) and polyorthoesters
or any other similar synthetic polymers that may be developed that
are biologically compatible. Some preferred synthetic matrix
materials include PLA, PGA, copolymers of PLA and PGA,
polycaprolactone, poly(ethylene-co-vinyl acetate), (EVOH), PVA, and
PEO. Matrices can be formed of electrospun fibers, electroaerosol,
electrosprayed, or electrosputtered droplets, or a combination of
the foregoing.
[0067] In embodiments in which natural materials are used, those
materials can be derived from a natural source, synthetically
manufactured, or manufactured by genetically engineered cells. For
example, genetically engineered proteins can be prepared with
specific desired sequences of amino acids that differ from the
natural proteins. In one illustrative embodiment, desirable
sequences that form binding sites on a collagen protein for cells
or peptides can be included in higher amounts than found in natural
collagen.
[0068] By selecting different materials, or combinations thereof,
many characteristics of the electroprocessed material can be
manipulated. The properties of the matrix comprised of
electroprocessed material and a substance may be adjusted. As
discussed in greater detail below, electroprocessed materials
themselves can provide a therapeutic effect when applied. In
addition, selection of matrix materials can affect the permanency
of an implanted matrix. For example, matrices made of fibrin will
degrade more rapidly while matrices made of collagen are more
durable and synthetic matrix materials are more durable still. Use
of matrices made of natural materials such as proteins also
minimize rejection or immunological response to an implanted
matrix. Accordingly selection of materials for electroprocessing
and use in substance delivery is influenced by the desired use. In
one embodiment, a skin patch of electroprocessed fibrin or collagen
combined with healing promoters and anti-rejection substances may
be applied to the skin and may subsequently dissolve into the skin.
In another embodiment, an implant for delivery to bone may be
constructed of materials useful for promoting bone growth,
osteoblasts and hydroxyapatite, and may be designed to endure for a
prolonged period of time.
[0069] Synthetic components, such as biocompatible substances can
be used to modulate the release of materials from an
electroprocessed composition. For example, a drug, or series of
drugs or other materials to be released in a controlled fashion can
be electroprocessed into a series of layers. One layer is composed
of PGA plus a drug, the next layer PLA plus a drug, a third layer
is composed of polycaprolactone plus a drug. The layered construct
can be implanted, and as the successive layers dissolve or
breakdown, the drug (or drugs) is released in turn as each
successive layer erodes. Unlayered structures can also be used, and
release is controlled by the relative stability of each component
of the construct. Another advantage of the synthetic materials is
that different solvents can be used. This can be important for the
delivery of some materials. For example, a drug may be soluble in
some organics, and using synthetics increases the number of
materials that can be electroprocessed. The breakdown of these
synthetic materials can be tailored and regulated in ways that are
not available to natural materials. The synthetics are usually not
subject to enzymatic breakdown, and many spontaneously undergo
hydrolysis. In addition to these characteristics, substances can be
released from electroprocessed materials in response to electrical,
magnetic and light based signals. Polymers that are sensitive to
such signals can be used, or the polymers may be derivatized in a
way to provide such sensitivity. These properties provide
flexibility in making and using electroprocessed materials designed
to deliver various substances, in vivo and in vitro.
[0070] In some embodiments of the present invention, the
electroprocessed material itself provides a therapeutic effect. For
example, in some embodiments electroprocessed collagen promotes
cellular infiltration and differentiation, so an electroprocessed
collagen matrix alone assists with healing. The P-15 site, a 15
amino acid sequence within the collagen molecule, promotes
osteoblasts to produce and to secrete hydroxyapatite, a component
of bone. Another example of specific sites and sequences within
collagen molecules that can be manipulated and processed in a
similar fashion includes the RGD binding sites of the integrin
molecule. The RGD site is a sequence of three amino acids
(Arg-Gly-Asp) present in many matrix materials that serves as a
binding site for cell adhesion. It is recognized and bound, for
example, by integrins. In addition, electroprocessed materials can
be enriched with specific desired sequences before, during, or
after electroprocessing. Sequences can be added in linear or other
forms. In some embodiments, the RGD sequences are arranged in a
cyclic form referred to as cycloRGD.
[0071] An electroprocessed material, such as a matrix, can also be
composed of specific subdomains of a matrix constituent and can be
prepared with a synthetic backbone that can be derivatized. For
example, the RGD peptide sequence, and/or a heparin binding domain
and/or other sequences, can be chemically coupled to synthetic
materials. The synthetic polymer with the attached sequence or
sequences can be electroprocessed into a construct. This produces a
matrix with unique properties. In these examples the RGD site
provides a site for cells to bind to and interact with the matrix.
The heparin-binding site provides a site for the anchorage of
peptide growth factors to the synthetic backbone. Angiogenic
peptides, genetic material, growth factors, cytokines, enzymes and
drugs are other non-limiting examples of substances that can be
attached to the backbone of an electroprocessed material to provide
functionality. Peptide side chains may also be used to attach
molecules to functional groups on polymeric backbones. Molecules
and other substances can be attached to a material to be
electroprocessed by any technique known in the art.
[0072] Another embodiment of matrix materials that have a
therapeutic effect is electroprocessed fibrin. Fibrin matrix
material assists in arrest of bleeding. Fibrin is a component of
the provisional matrix that is laid down during the early stages of
healing and may also promote the growth of vasculature in adjacent
regions, and in many other ways is a natural healing promoter.
Fibrinogen as an electroprocessed material can also assist in
healing. When placed in contact with a wound, for example,
fibrinogen will react with thrombin present in the blood plasma
from the wound and form fibrin, thereby providing the same healing
properties of a fibrin material.
[0073] Substances
[0074] As discussed above, the word "substance" in the present
invention is used in its broadest definition. In embodiments in
which the compositions of the present invention comprise one or
more substances, substances can include any type or size of
molecules, cells, objects or combinations thereof. The compositions
of the present invention may comprise one substance or any
combination of substances.
[0075] In embodiments in which the substances are molecules, any
molecule can be used. Molecules may, for example, be organic or
inorganic and may be in a solid, semisolid, liquid, or gas phase.
Molecules may be present in combinations or mixtures with other
molecules, and may be in solution, suspension, or any other form.
Examples of classes of molecules that may be used include human or
veterinary therapeutics, cosmetics, nutraceuticals, agriculturals
such as herbicides, pesticides and fertilizers, vitamins, amino
acids, peptides, polypeptides, proteins, carbohydrates, lipids,
nucleic acids, glycoproteins, lipoproteins, glycolipids,
glycosaminoglycans, proteoglycans, growth factors, hormones,
neurotransmitters, pheromones, chalones, prostaglandins,
immunoglobulins, monokines and other cytokines, humectants, metals,
gases, minerals, ions, electrically and magnetically reactive
materials, light sensitive materials, anti-oxidants, molecules that
may be metabolized as a source of cellular energy, antigens, and
any molecules that can cause a cellular or physiological response.
Any combination of molecules can be used as well as agonists or
antagonists.
[0076] Several preferred embodiments use therapeutic molecules
include use of any therapeutic molecule including, without
limitation, any pharmaceutical or drug. Examples of pharmaceuticals
include, but are not limited to, anesthetics, hypnotics, sedatives
and sleep inducers, antipsychotics, antidepressants, antiallergics,
antianginals, antiarthritics, antiasthmatics, antidiabetics,
antidiarrheal drugs, anticonvulsants, antigout drugs,
antihistamines, antipruritics, emetics, antiemetics,
antispasmondics, appetite suppressants, neuroactive substances,
neurotransmitter agonists, antagonists, receptor blockers and
reuptake modulators, beta-adrenergic blockers, calcium channel
blockers, disulfarim and disulfarim-like drugs, muscle relaxants,
analgesics, antipyretics, stimulants, anticholinesterase agents,
parasympathomimetic agents, hormones, anticoagulants,
antithrombotics, thrombolytics, immunoglobulins,
immunosuppressants, hormone agonists/antagonists, vitamins,
antimicrobial agents, antineoplastics, antacids, digestants,
laxatives, cathartics, antiseptics, diuretics, disinfectants,
fungicides, ectoparasiticides, antiparasitics, heavy metals, heavy
metal antagonists, chelating agents, gases and vapors, alkaloids,
salts, ions, autacoids, digitalis, cardiac glycosides,
antiarrhythmics, antihypertensives, vasodilators, vasoconstrictors,
antimuscarinics, ganglionic stimulating agents, ganglionic blocking
agents, neuromuscular blocking agents, adrenergic nerve inhibitors,
anti-oxidants, vitamins, cosmetics, anti-inflammatories, wound care
products, antithrombogenic agents, antitumoral agents,
antithrombogenic agents, antiangiogenic agents, anesthetics,
antigenic agents, wound healing agents, plant extracts, growth
factors, emollients, humectants, rejection/anti-rejection drugs,
spermicides, conditioners, antibacterial agents, antifungal agents,
antiviral agents, antibiotics, tranquilizers, cholesterol-reducing
drugs, antitussives, histamine-blocking drugs, monoamine oxidase
inhibitor. All substances listed by the U.S. Pharmacopeia are also
included within the substances of the present invention.
[0077] Antibiotics useful in the present invention include, but are
not limited to, amoxicillin, amphotericin, ampicillin, bacitracin,
beclomethasone, benzocaine, betamethasone, biaxin, cephalosporins,
chloramphenicol, ciprofloxacin, clotrimazole, cyclosporin,
docycline, enoxacin, erythromycin, gentamycin, miconazole,
neomycin, norfloxacin, nystatin, ofloxacin, pefloxacin, penicillin,
pentoxifylline, phenoxymethylpenicillin, polymixin, rifampicin,
tetracycline, tobrmycin, triclosan, vancomycin, zithromax,
derivatives, metabolites, and mixtures thereof, or compounds having
similar antimicrobial activity.
[0078] Some specific examples of pharmaceutical agents that are
useful as substances include, but are not limited to, quinolones,
such as oxolinic acid, norfloxacin, and nalidixic acid,
sulfonamides, nonoxynol 9, fusidic acid, cephalosporins,
cyclosporine, acebutolol, acetylcysteine, acetylsalicylic acid,
acyclovir, AZT, alprazolam, alfacalcidol, allantoin, allopurinol,
ambroxol, amikacin, amiloride, aminoacetic acid, aminodarone,
amitriptyline, amlodipine, ascorbic acid, aspartame, astemizole,
atenolol, benserazide, benzalkonium hydrochloride, benzoic acid,
bezafibrate, biotin, biperiden, bisoprolol, bromazepam, bromhexine,
bromocriptine, budesonide, bufexamac, buflomedil, buspirone,
caffeine, camphor, captopril, carbamazepine, carbidopa,
carboplatin, cefachlor, cefalexin, cefatroxil, cefazolin, cefixime,
cefotaxime, ceftazidime, ceftriaxone, cefuroxime, selegiline,
chloramphenicol, chlorpheniramine, chlortalidone, choline,
cilastatin, cimetidine, cisapride, cisplatin, clarithromycin,
clavulanic acid, clomipramine, clozapine, clonazepam, clonidine,
codeine, cholestyramine, cromoglycic acid, cyanocobalamin,
cyproterone, desogestrel, dexamethasone, dexpanthenol,
dextromethorphan, dextropropoxiphen, diazepam, diclofenac, digoxin,
dihydrocodeine, dihydroergotamine, dihydroergotoxin, diltiazem,
diphenhydramine, dipyridamole, dipyrone, disopyramide, domperidone,
dopamine, doxycycline, enalapril, ephedrine, epinephrine,
ergocalciferol, ergotamine, erythromycin, estradiol,
ethinylestradiol, etoposide, Eucalyptus globulus, famotidine,
felodipine, fenofibrate, fenoterol, fentanyl, flavin
mononucleotide, fluconazole, flunarizine, fluorouracil, fluoxetine,
flurbiprofen, furosemide, gallopamil, gemfibrozil, Gingko biloba,
glibenclamide, glipizide, Glycyrrhiza glabra, grapefruit seed
extract, grape seed extract, griseofulvin, guaifenesin,
haloperidol, heparin, hyaluronic acid, hydrochlorothiazide,
hydrocodone, hydrocortisone, hydromorphone, ipratropium hydroxide,
ibuprofen, imipenem, indomethacin, iohexyl, iopamidol, isosorbide
dinitrate, isosorbide mononitrate, isotretinoin, ketotifen,
ketoconazole, ketoprofen, ketorolac, labetalol, lactulose,
lecithin, levocarnitine, levodopa, levoglutamide, levonorgestrel,
levothyroxine, lidocaine, lipase, imipramine, lisinopril,
loperamide, lorazepam, lovastatin, medroxyprogesterone, menthol,
methotrexate, methyldopa, methylprednisolone, metoclopramide,
metoprolol, miconazole, midazolam, minocycline, minoxidil,
misoprostol, morphine, N-methylephedrine, naftidrofuryl, naproxen,
nicardipine, nicergoline, nicotinamide, nicotine, nicotinic acid,
nifedipine, nimodipine, nitrazepam, nitrendipine, nizatidine,
norethisterone, norfloxacin, norgestrel, nortriptyline, omeprazole,
ondansetron, pancreatin, panthenol, pantothenic acid, paracetamol,
phenobarbital, derivatives, metabolites, and other such compounds
have similar activity. Some preferred drugs or compounds include,
but are not limited to, estrogen, androgen, cortisone, and
cyclosporin.
[0079] Growth factors useful in the present invention include, but
are not limited to, transforming growth factors ("TGF-.alpha."),
transforming growth factor-.beta. ("TGF-.beta."), platelet-derived
growth factors ("PDGF"), fibroblast growth factors ("FGF"),
including FGF acidic isoforms 1 and 2, FGF basic form 2 and FGF 4,
8, 9 and 10, nerve growth factors ("NGF") including NGF 2.5s, NGF
7.0s and beta NGF and neurotrophins, brain derived neurotrophic
factor, cartilage derived factor, bone growth factors (BGF), basic
fibroblast growth factor, insulin-like growth factor (IGF),
vascular endothelial growth factor (VEGF), granulocyte colony
stimulating factor (G-CSF), insulin like growth factor (IGF) I and
II, hepatocyte growth factor, glial neurotrophic growth factor
(GDNF), stem cell factor (SCF), keratinocyte growth factor (KGF),
transforming growth factors (TGF), including TGFs alpha, beta,
beta1, beta2, beta3, skeletal growth factor, bone matrix derived
growth factors, and bone derived growth factors and mixtures
thereof.
[0080] Cytokines useful in the present invention include, but are
not limited to, cardiotrophin, stromal cell derived factor,
macrophage derived chemokine (MDC), melanoma growth stimulatory
activity (MGSA), macrophage inflammatory proteins 1 alpha (MIP-1
alpha), 2, 3 alpha, 3 beta, 4 and 5, IL4, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TNF-.alpha.,
and TNF-.beta.. Immunoglobulins useful in the present invention
include, but are not limited to, IgG, IgA, IgM, IgD, IgE, and
mixtures thereof. Some preferred growth factors include VEGF
(vascular endothelial growth factor), NGFs (nerve growth factors),
PDGF-AA, PDGF-BB, PDGF-AB, FGFb, FGFa, and BGF.
[0081] Other molecules useful as substances in the present
invention include but are not limited to growth hormones, leptin,
leukemia inhibitory factor (LIF), tumor necrosis factor alpha and
beta, endostatin, thrombospondin, osteogenic protein-1, bone
morphogenetic proteins 2 and 7, osteonectin, somatomedin-like
peptide, osteocalcin, interferon alpha, interferon alpha A,
interferon beta, interferon gamma, interferon 1 alpha, and
interleukins 2, 3, 4, 5 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17 and
18.
[0082] Embodiments involving amino acids, peptides, polypeptides,
and proteins may include any type or combinations of such molecules
of any size and complexity. Examples include, but are not limited
to structural proteins, enzymes, and peptide hormones. These
compounds can serve a variety of functions. In some embodiments,
the matrix may contain peptides containing a sequence that
suppresses enzyme activity through competition for the active site.
In other applications antigenic agents that promote an immune
response and invoke immunity can be incorporated into a
construct.
[0083] In substances such as nucleic acids, any nucleic acid can be
present. Examples include, but are not limited to deoxyribonucleic
acid (DNA), ent-DNA, and ribonucleic acid (RNA). Embodiments
involving DNA include, but are not limited to, cDNA sequences,
natural DNA sequences from any source, and sense or anti-sense
oligonucleotides. For example, DNA can be naked (e.g., U.S. Pat.
Nos. 5,580,859; 5,910,488) or complexed or encapsulated (e.g., U.S.
Pat. Nos. 5,908,777; 5,787,567). DNA can be present in vectors of
any kind, for example in a viral or plasmid vector. In some
embodiments, nucleic acids used will serve to promote or to inhibit
the expression of genes in cells inside and/or outside the
electroprocessed matrix. The nucleic acids can be in any form that
is effective to enhance its uptake into cells.
Cells as a Substance
[0084] In embodiments in which cells are a substance, any cell can
be used. Cells that can be used include, but are not limited to
stem cells, committed stem cells, and differentiated cells.
Examples of stem cells that can be used include but are not limited
to embryonic stem cells, bone marrow stem cells and umbilical cord
stem cells. Other examples of cells used in various embodiments
include but are not limited to: osteoblasts, myoblasts,
neuroblasts, fibroblasts, glioblasts; germ cells, hepatocytes,
chondrocytes, keratinocytes, smooth muscle cells, cardiac muscle
cells, connective tissue cells, epithelial cells, endothelial
cells, hormone-secreting cells, cells of the immune system, and
neurons. In some embodiments it is unnecessary to pre-select the
type of stem cell that is to be used, because many types of stem
cells can be induced to differentiate in an organ specific pattern
once delivered to a given organ. For example, a stem cell delivered
to the liver can be induced to become a liver cell simply by
placing the stem cell within the biochemical environment of the
liver. Cells in the matrix can serve the purpose of providing
scaffolding or seeding, producing certain compounds, or both.
[0085] Embodiments in which the substance comprises cells include
cells that can be cultured in vitro, derived from a natural source,
or produced by any other means. Any natural source of prokaryotic
or eukaryotic cells may be used. Embodiments in which the matrix is
implanted in an organism can use cells from the recipient, cells
from a conspecific donor or a donor from a different species, or
bacteria or microbial cells. Cells harvested from a source and
cultured prior to use are also included.
[0086] Some embodiments use cells that have been genetically
engineered. The engineering involves programming the cell to
express one or more genes, repressing the expression of one or more
genes, or both. One example of genetically engineered cells useful
in the present invention is a genetically engineered cell that
makes and secretes one or more desired molecules. When
electroprocessed matrices comprising genetically engineered cells
are implanted in an organism, the molecules produced can produce a
local effect or a systemic effect, and can include the molecules
identified above as possible substances. Cells can also produce
antigenic materials in embodiments in which one of the purposes of
the matrix is to produce an immune response. Cells may produce
substances to aid in the following non-inclusive list of purposes:
inhibit or stimulate inflammation; facilitate healing; resist
immunorejection; provide hormone replacement; replace
neurotransmitters; inhibit or destroy cancer cells; promote cell
growth; inhibit or stimulate formation of blood vessels; augment
tissue; and to supplement or replace the following tissue, neurons,
skin, synovial fluid, tendons, cartilage, ligaments, bone, muscle,
organs, dura, blood vessels, bone marrow, and extracellular
matrix.
[0087] Genetic engineering can involve, for example, adding or
removing genetic material to or from a cell, altering existing
genetic material, or both. Embodiments in which cells are
transfected or otherwise engineered to express a gene can use
transiently or permanently transfected genes, or both. Gene
sequences may be full or partial length, cloned or naturally
occurring.
[0088] Substances in the electroprocessed compositions of the
present invention also comprise objects. Examples of objects
include, but are not limited to, cell fragments, cell debris,
organelles and other cell components, tablets, and viruses as well
as vesicles, liposomes, capsules, nanoparticles, and other
structures that serve as an enclosure for molecules. In some
embodiments, the objects constitute vesicles, liposomes, capsules,
or other enclosures that contain compounds that are released at a
time after electroprocessing, such as at the time of implantation
or upon later stimulation or interaction. In one illustrative
embodiment, transfection agents such as liposomes contain desired
nucleotide sequences to be incorporated into cells that are located
in or on the electroprocessed material or matrix. In other
embodiments, cell fragments or cell debris are incorporated into
the matrix. The presence of cell fragments is known to promote
healing in some tissues.
[0089] Magnetically or electrically reactive materials are also
examples of substances that are optionally included within
compositions of the present invention. Examples of magnetically
active materials include but are not limited to carbon black or
graphite, carbon nanotubes, ferrofluids (colloidal suspensions of
magnetic particles), and various dispersions of electrically
conducting polymers. Ferrofluids containing particles approximately
10 nm in diameter, polymer-encapsulated magnetic particles about
1-2 microns in diameter, and polymers with a glass transition
temperature below room temperature are particularly useful.
Examples of electrically active polymers include, but are not
limited to, electrically conducting polymers such as polyanilines,
polypyrroles and ionically conducting polymers such as sulfonated
polyacrylamides are related materials.
[0090] In other embodiments, some substances in the
electroprocessed material or matrix supplement or augment the
function of other substances. For example, when the composition
comprises cells that express a specific gene, the composition can
contain oligonucleotides that are taken up by the cells and affect
gene expression in the cells. Fibronectin is optionally
incorporated into the matrix to increase cellular uptake of
oligonucleotides by pinocytosis.
[0091] As discussed in detail above, the electroprocessed material
itself can provide a therapeutic effect. The invention thus
includes embodiments involving methods of causing a therapeutic
effect through delivery of an electroprocessed material to a
location without incorporating additional substances in the
electroprocessed material. Embodiments in which the matrix material
alone is delivered as well as those in which other substances are
included in the matrix are within the scope of the present
invention.
Methods of Making the Composition
[0092] Electroprocessing
[0093] The method of making the compositions includes
electroprocessing the materials and optionally electroprocessing
the substances. As defined above, one or more electroprocessing
techniques, such as electrospin, electrospray, electroaerosol,
electrosputter or any combination thereof may be employed to make
the electroprocessed materials and matrices in the compositions of
the present invention. In the most fundamental sense, the
electroprocessing apparatus for electroprocessing material includes
a electrodepositing mechanism and a target substrate. The
electrodepositing mechanism includes a reservoir or reservoirs to
hold the one or more solutions that are to be electroprocessed or
electrodeposited. The reservoir or reservoirs have at least one
orifice or nozzle to allow the streaming of the solution from the
reservoirs. One or a plurality of nozzles may be configured in an
electroprocessing apparatus. If there are multiple nozzles, each
nozzle is attached to one or more reservoirs containing the same or
different solutions. Similarly, there can be a single nozzle that
is connected to multiple reservoirs containing the same or
different solutions. Multiple nozzles may be connected to a single
reservoir. Because different embodiments involve single or multiple
nozzles and/or reservoirs, any references herein to one or nozzles
or reservoirs should be considered as referring to embodiments
involving single nozzles, reservoirs, and related equipment as well
as embodiments involving plural nozzles, reservoirs, and related
equipment. The size of the nozzles can be varied to provide for
increased or decreased flow of solutions out of the nozzles. One or
more pumps used in connection with the reservoirs can be used to
control the flow of solution streaming from the reservoir through
the nozzle or nozzles. The pump can be programmed to increase or
decrease the flow at different points during electroprocessing. In
this invention pumps are not necessary but provide a useful method
to control the rate at which material is delivered to the electric
field for processing. Material can be actively delivered to the
electric field as a preformed aerosol using devices such as air
brushes, thereby increasing the rate of electrodeposition and
providing novel combinations of materials. Nozzles may be
programmed to deliver material simultaneously or in sequence.
[0094] The electroprocessing occurs due to the presence of a charge
in either the orifices or the target, while the other is grounded.
In some embodiments, the nozzle or orifice is charged and the
target is shown to be grounded. Those of skill in the
electroprocessing arts will recognize that the nozzle and solution
can be grounded and the target can be electrically charged. The
creation of the electrical field and the effect of the electrical
field on the electroprocessed materials or substances that will
form the electroprocessed composition.
[0095] The target substrate can also be used as a variable feature
in the electroprocessing of materials used to make the
electroprocessed composition. Specifically, the target can be the
actual substrate for the materials used to make electroprocessed
matrix, or electroprocessed matrix itself is deposited.
Alternatively, a substrate can be disposed between the target and
the nozzles. For instance, a petri dish can be disposed between a
nozzles and a target, and a matrix can be formed in the dish. Other
variations include but are not limited to non-stick surfaces
between the nozzles and target and placing tissues or surgical
fields between the target and nozzles. The target can also be
specifically charged or grounded along a preselected pattern so
that the solution streamed from the orifice is directed into
specific directions. The electric field can be controlled by a
microprocessor to create an electroprocessed matrix having a
desired geometry. The target and the nozzle or nozzles can be
engineered to be movable with respect to each other thereby
allowing additional control over the geometry of the
electroprocessed matrix to be formed. The entire process can be
controlled by a microprocessor that is programmed with specific
parameters that will obtain a specific preselected electroprocessed
matrix. It is to be understood that any electroprocessing technique
may be used, alone or in combination with another electroprocessing
technique, to make the compositions of the present invention.
[0096] Any material that can be electroprocessed is within the
method of the present invention. Forms of electroprocessed collagen
include but are not limited to preprocessed collagen in a liquid
suspension or solution, gelatin, particulate suspension, or
hydrated gel. An example for fibrin is a preformed gel
electroprocessed by subjecting it to pressure, for example by using
a syringe or airbrush apparatus with a pressure head behind it to
extrude the fibrin gel into the electrical field. In general, when
producing fibers using electroprocessing techniques, especially
electrospinning, it is preferable to use the monomer of the polymer
fiber to be formed. In some embodiments it is desirable to use
monomers to produce finer filaments. In other embodiments, it is
desirable to include partial fibers to add material strength to the
matrix and to provide additional sites for incorporating
substances. Matrix materials such as collagen in a gelatin form may
be used to improve the ability of the material to dissolve. Acid
extraction method can be used in preparing such gels to maintain
the structure of the monomeric subunits. Units can then be treated
with enzymes to alter the structure of the monomers.
[0097] In embodiments in which two materials combine to form a
third material, the solutions containing these components can be
mixed together immediately before they are streamed from an orifice
in the electroprocessing procedure. In this way, the third material
forms literally as the microfibers or microdroplets are formed in
the electrospinning process. Alternatively, such matrices can be
formed by electrospraying a molecule that can form matrix materials
into a moist or otherwise controlled atmosphere of other molecules
necessary to allow formation of the matrix to form filaments within
the electric field. For example, fibrinogen can be sprayed into a
moist atmosphere of thrombin. Materials such as fibrinogen that are
capable of forming other materials such as fibrin can also be
electrosprayed onto a target that has thrombin. Alternatively
thrombin can also be electrosprayed onto a target that has
fibrinogen.
[0098] In embodiments in which two or more matrix materials are
combined to form a third (for example, combining fibrinogen and
thrombin to form fibrin) the matrix materials can be
electroprocessed in conjunction with or separately from each other,
typically under conditions that do not allow the two molecules to
form the third until the desired time. This can be accomplished
several ways. Using fibrinogen and thrombin as an example, the two
matrix materials can be electroprocessed from a solvent that does
not allow thrombin to function. Alternatively, the fibrinogen or
thrombin can be packaged in a carrier material. In this application
the fibrinogen is electroprocessed onto the target from one
solution source (by itself or with a carrier), and the thrombin is
deposited in an electroaerosol manner from a separate source. The
thrombin can be encapsulated and sprayed as a fine mist of
particles. Alternatively, thrombin and fibrinogen can be mixed with
a carrier, such as PEG, or other synthetic or natural polymers such
as collagen. The carrier acts to hold the reactants in place until
they are initiated. These methods are not limited to thrombin and
fibrinogen and also are used with embodiments involving other
combinations of matrix materials that combine to form a third
material. The entire product is preferably stored under dry
conditions to prevent the reaction of the two materials. When the
material is placed in a moist environment, the materials are able
to combine and the product matrix material is formed.
[0099] As stated above, it is to be understood that carriers can be
used in conjunction with matrix materials. Different materials,
such as extracellular matrix proteins, and or substances, can be
mixed with PEG or other known carriers that form filaments. For
example, fibrinogen and collagen can be mixed with PEG or other
known carriers that form filaments. This produces "hairy filaments"
with the hair being fibrin. The "hairs" cross-link the surrounding
matrix carrier into a gel, or provide reactive sites for cells to
interact with the substance within the matrix carrier, such as
immunoglobulins. This approach can be used for forming a matrix or
gelling molecules that do not normally gel. For example, in
embodiments in which a specific type of matrix material will not
form filaments, then the matrix material can be combined with
fibrin and PEG and electrosprayed to form an electroprocessed
fibrin-containing matrix. Once fibrin formation begins, a gel of
the matrix material and fibrin together is produced.
[0100] Alternatively, the material can be sputtered with another
molecule that forms a sheet. Examples of molecules that form sheets
include PGA, PLA, a copolymer of PGA and PLA, collagen, and
fibronectin. In some embodiments, a sheet is formed with two or
more materials that can combine to form a third material. This
sheet can be placed in a wet environment to allow conversion to the
third material.
[0101] In addition to the multiple equipment variations and
modifications that can be made to obtain desired results, similarly
the electroprocessed solution can be varied to obtain different
results. For instance, any solvent or liquid in which the material
is dissolved, suspended, or otherwise combined without deleterious
effect on the process or the safe use of the matrix can be used.
Materials or the compounds that form materials can be mixed with
other molecules, monomers or polymers to obtained desired results.
In some embodiments, polymers are added to modify the viscosity of
the solution. In still a further variation, when multiple
reservoirs are used, the ingredients in those reservoirs are
electrosprayed separately or joined at the nozzle so that the
ingredients in the various reservoirs can react with each other
simultaneously with the streaming of the solution into the electric
field. Also, when multiple reservoirs are used, the different
ingredients in different reservoirs can be phased in temporally
during the processing period. These ingredients may include
substances.
[0102] Embodiments involving alterations to the electroprocessed
materials themselves are within the scope of the present invention.
Some materials can be directly altered, for example, by altering
their carbohydrate profile. Also, other materials can be attached
to the matrix materials before, during or after electroprocessing
using known techniques such as chemical cross-linking or through
specific binding interactions (e.g. PDGF binds to collagen at a
specific binding site). Further, the temperature and other physical
properties of the process can be modified to obtain different
results. The matrix may be compressed or stretched to produce novel
material properties.
[0103] Still further chemical variations are possible. Fibrin, for
example, is formed in different ways. Building an electroprocessed
matrix comprised of fibrin, therefore, involves different ways of
bringing the molecules capable of forming fibrin, such as
fibrinogen and thrombin, together through electroprocessing
methods. Electroprocessed materials and matrices can also be
manipulated after they are formed with the electroprocessing
methods.
[0104] A matrix of electroprocessed fibers, in accordance with the
present invention, can be produced as described below. In the case
of electrospun fibrin, while any molecules capable of forming
fibrin can be used, it is preferable to electroprocess fibrinogen
or thrombin to make fibrin fibers.
[0105] Electroprocessing using multiple jets of different polymer
solutions and/or the same solutions with different types and
amounts of substances (e.g., growth factors) can be used to prepare
libraries of biomaterials for rapid screening. Such libraries are
desired by those in the pharmaceutical, advanced materials and
catalyst industries using combinatorial synthesis techniques for
the rapid preparation of large numbers (e.g., libraries) of
compounds that can be screened. For example, the minimum amount of
growth factor to be released and the optimal release rate from a
fibrous polymer scaffold to promote the differentiation of a
certain type of cell can be investigated using the compositions and
methods of the present invention. Other variables include fiber
diameter and fiber composition. Electroprocessing permits access to
an array of samples on which cells can be cultured in parallel and
studied to determine selected compositions which serve as promising
cell growth substrates.
[0106] Various effective conditions can be used to electroprocess a
matrix. While the following is a description of a preferred method,
other protocols can be followed to achieve the same result.
Referring to FIG. 1 in electrospinning fibers, micropipettes 10 are
filled with materials and suspended above a grounded target 11, for
instance, a metal ground screen placed inside the central cylinder
of the RCCS bioreactor. Although this embodiment involves two
micropipettes acting as sources of materials, the present invention
includes embodiments involving only one source or more than two
sources. A fine wire 12 is placed in the solution to charge the
solution in each pipette tip 13 to a high voltage. At a specific
voltage determined for each solution and apparatus arrangement, the
solution suspended in each pipette tip is directed towards the
grounded target. This stream 14 of materials may form a continuous
filament, for example when collagen is the material, that upon
reaching the grounded target, collects and dries to form a
three-dimensional, ultra thin, interconnected matrix of
electroprocessed collagen fibers. Depending upon reaction
conditions a single continuous filament may be formed and deposited
in a non-woven matrix.
[0107] As noted above, combinations of electroprocessing techniques
and substances are used in some embodiments. Referring now to FIG.
2, micropipette tips 13 are each connected to micropippettes 10
that contain different materials or substances. The micropipettes
are suspended above a grounded target 11. Again, fine wires 12 are
used to charge the solutions. One micropipette produces a stream of
collagen fibers 14. Another micropipette produces a steam of
electrospun PLA fibers 16. A third micropipette produces an
electroaerosol of cells 17. A fourth micropipette produces an
electrospray of PLA droplets 18. Although the micropipettes are
attached to the same voltage supply 15, PLA is electrosprayed
rather than electrospun from the fourth micropipette due to
variation in the concentration of PLA in the solutions.
Alternatively, separate voltage supplies (not shown) can be
attached to each micropipette to allow varying electroprocessing
methods to be used through application of different voltage
potentials.
[0108] Similarly, referring now to FIG. 8, the same material can be
applied as electrospun fibers 19 from one of the two micropipettes
and electrosprayed droplets 20 from the other micropipette disposed
at a different angles with respect to the grounded substrate 11.
Again, the micropipette tips 13 are attached to micropipettes 10
that contain varying concentrations of materials and thus produce
different types of electroprocessed streams despite using the same
voltage supply 15 through fine wires 12.
[0109] Minimal electrical current is involved in this process, and,
therefore, electroprocessing, in this case electrospinning, does
not denature the materials that form the electroprocessed
materials, because the current causes little or no temperature
increase in the solutions during the procedure. In melt
electrospinning, there is some temperature increase associated with
the melting of the material. In such embodiments, care is exercised
to assure that the materials or substances are not exposed to
temperatures that will denature or otherwise damage or injure
them.
[0110] An electroaerosoling process can be used to produce a dense,
matte-like matrix of electroprocessed droplets of material. The
electroaerosoling process is a modification of the electrospinning
process in that the electroaerosol process utilizes a lower
concentration of matrix materials or molecules that form
electroprocessed materials during the procedure. Instead of
producing a splay of fibers or a single filament at the charge tip
of the nozzle, small droplets are formed. These droplets then
travel from the charged tip to the grounded substrate to form a
sponge-like matrix composed of fused droplets. In some embodiments,
the droplets are less than 10 microns in diameter. In other
embodiments a construct composed of fibrils with droplets, like
"beads on a string" may be produced. Droplets may range in size
from 100 nanometers to 10 microns depending on the polymer and
solvents.
[0111] As with the electrospinning process described earlier, the
electroaerosol process can be carried out using various effective
conditions. The same apparatus that is used in the electrospinning
process, for instance as shown in FIG. 1, is utilized in the
electroaerosol process. The differences from electrospinning
include the concentration of the materials or substances that form
matrix materials placed in solution in the micropipette reservoir
and/or the voltage used to create the stream of droplets.
[0112] One of ordinary skill in the art recognizes that changes in
the concentration of materials or substances in the solutions
requires modification of the specific voltages to obtain the
formation and streaming of droplets from the tip of a pipette.
[0113] The electroprocessing process can be manipulated to meet the
specific requirements for any given application of the
electroprocessed compositions made with these methods. In one
embodiment, the micropipettes can be mounted on a frame that moves
in the x, y and z planes with respect to the grounded substrate.
The micropipettes can be mounted around a grounded substrate, for
instance a tubular mandrel. In this way, the materials or molecules
that form materials streamed from the micropipettes can be
specifically aimed or patterned. Although the micropipettes can be
moved manually, the frame onto which the micropipettes are mounted
is preferably controlled by a microprocessor and a motor that allow
the pattern of streaming collagen to be predetermined by a person
making a specific matrix. Such microprocessors and motors are known
to one of ordinary skill in the art. For instance, matrix fibers or
droplets can be oriented in a specific direction, they can be
layered, or they can be programmed to be completely random and not
oriented.
[0114] In the electrospinning process, the stream or streams can
branch out to form fibers. The degree of branching can be varied by
many factors including, but not limited to, voltage, ground
geometry, distance from micropipette tip to the substrate, diameter
of micropipette tip, and concentration of materials or compounds
that will form the electroprocessed materials. As noted, not all
reaction conditions and polymers may produce a true multifilament,
under some conditions a single continuous filament is produced.
Materials and various combinations can also be delivered to the
electric field of the system by injecting the materials into the
field from a device that will cause them to aerosol. This process
can be varied by many factors including, but not limited to,
voltage (for example ranging from about 0 to 30,000 volts),
distance from micropipette tip to the substrate (for example from
0-40 cm), the relative position of the micropipette tip and target
(i.e. above, below, aside etc.), and the diameter of micropipette
tip (approximately 0-2 mm). Several of these variables are
well-known to those of skill in the art of electrospinning
microfiber textile fabrics.
[0115] The geometry of the grounded target can be modified to
produce a desired matrix. By varying the ground geometry, for
instance having a planar or linear or multiple points ground, the
direction of the streaming materials can be varied and customized
to a particular application. For instance, a grounded target
comprising a series of parallel lines can be used to orient
electrospun materials in a specific direction. The grounded target
can be a cylindrical mandrel whereby a tubular matrix is formed.
Most preferably, the ground is a variable surface that can be
controlled by a microprocessor that dictates a specific ground
geometry that is programmed into it. Alternatively, for instance,
the ground can be mounted on a frame that moves in the x, y, and z
planes with respect to a stationary micropipette tip streaming
collagen.
[0116] The substrate onto which the materials are streamed, sprayed
or sputtered can be the grounded target itself or it can be placed
between the micropipette tip and the grounded target The substrate
can be specifically shaped, for instance in the shape of a nerve
guide, skin patch, fascial sheath, or a vascular graft for
subsequent use in vivo. The electroprocessed compositions can be
shaped to fit a defect or site to be filled. Examples include a
site from which a tumor has been removed, an injury site in the
skin (a cut, a biopsy site, a hole or other defect) and a missing
or shattered piece of bone. The electroprocessed compositions may
be shaped into shapes useful for substance delivery, for example, a
skin patch, a lozenge for ingestion, an intraperitoneal implant, a
subdermal implant, the interior lining of a stent, a cardiovascular
valve, a tendon, a ligament a dental prosthesis, a muscle implant,
or a nerve guide. Electroprocessing allows great flexibility and
allows for customizing the construct to virtually any shape needed.
Many matrices are sufficiently flexible to allow them to be formed
to virtually any shape. In shaping matrices, portions of the matrix
may be sealed to one another by, for example, heat sealing,
chemical sealing, and application of mechanical pressure or a
combination thereof. An example of heat sealing is the use of
crosslinking techniques discussed herein to form crosslinking
between two portions of the matrix. Sealing may also be used to
close an opening in a shaped matrix. Suturing may also be used to
attach portions of matrices to one another or to close an opening
in a matrix. It has been observed that inclusion of synthetic
polymers enhances the ability of matrices to be heat sealed.
[0117] Other variations of electroprocessing, particularly
electrospinning and electroaerosoling include, but are not limited
to the following:
[0118] 1. Using different solutions to produce two or more
different fibers or droplets simultaneously (fiber or droplet
array). In this case, the single component solutions can be
maintained in separate reservoirs.
[0119] 2. Using mixed solutions (for example, materials along with
substances such as cells, growth factors, or both) in the same
reservoir(s) to produce fibers or droplets composed of
electroprocessed materials as well as one or more substances (fiber
composition "blends"). Nonbiological but biologically compatible
material can be mixed with a biological molecule.
[0120] 3. Utilizing multiple potentials applied for the different
solutions or the same solutions.
[0121] 4. Providing two or more geometrically different grounded
targets (i.e. small and large mesh screens).
[0122] 5. Placing the mold or mandrel or other ungrounded target in
front of the grounded target
[0123] 6. Applying agents such as Teflon onto the target to
facilitate the removal of electroprocessed materials from the
target (i.e. make the material more slippery so that the
electroprocessed materials do not stick to the target).
[0124] 7. Forming an electroprocessed material that includes
materials applied using multiple electroprocessing methods. For
example, electrospun fibers and electroaerosol droplets in the same
composition can be beneficial for some applications depending on
the particular structure desired. This combination of fibers and
droplets can be obtained by using the same micropipette and
solution and varying the electrical charge; varying the distance
from the grounded substrate; varying the polymer concentration in
the reservoir, using multiple micropipettes, some for streaming
fibers and others for streaming droplets; or any other variations
to the method envisioned by those of skill in this art. The fibers
and droplets can be layered or mixed together in same layers. In
applications involving multiple micropipettes, the micropipettes
can be disposed in the same or different directions and distances
with reference to the target.
[0125] 8. Using multiple targets.
[0126] All these variations can be done separately or in
combination to produce a wide variety of electroprocessed materials
and substances.
[0127] The various properties of the electroprocessed materials can
be adjusted in accordance with the needs and specifications of the
cells to be suspended and grown within them. The porosity, for
instance, can be varied in accordance with the method of making the
electroprocessed materials or matrix. Electroprocessing a
particular matrix, for instance, can be varied by fiber (droplet)
size and density. If the cells to be grown in the matrix require a
great deal of nutrient flow and waste expulsion, then a loose
matrix can be created. On the other hand, if the tissue to be made
requires a very dense environment, then a dense matrix can be
designed. Porosity can be manipulated by mixing salts or other
extractable agents. Removing the salt will leave holes of defined
sizes in the matrix.
[0128] One embodiment for appropriate conditions for
electroprocessing fibrin is presented below. For electroprocessing
fibrin by combining fibrinogen and thrombin, the appropriate
approximate ranges are: voltage 0-30,000 volts; pH 7.0 to 7.4;
calcium 3 to 10 mM; temperature 20 to 40.degree. C.; ionic strength
0.12 to 0.20 M; thrombin 0.1 to 1.0 units per ml; and fibrinogen 5
to 25 mg/ml. For electroprocessing fibrin monomer, the pH starts at
5 and increases to 7.4 while the ionic strength starts above 0.3 M
and decreases to 0.1 M. The other conditions are similar as stated
within this paragraph. Electroprocessed fibrin matrices of varying
properties can be engineered by shifting the pH, changing the ionic
strength, altering the calcium concentration, or adding additional
polymeric substrates or cationic materials. For electroprocessing
collagen, the appropriate approximate ranges are: voltage 0-30,000
volts; pH 7.0 to 8.0; temperature 20 to 42.degree. C.; and collagen
0 to 5 mg/ml. Electroprocessed collagen matrices of varying
properties can be engineered by shifting the pH, changing the ionic
strength (e.g. addition of organic salts), or adding additional
polymeric substrates or cationic materials.
[0129] Shapes of Electroprocessed Materials and Matrices
Electroprocessed materials can be electrodeposited inside a
specifically shaped mold. For instance, a particular type of organ
or tissue that to be replaced has a specific shape, such as a skin
patch to fit a biopsy site or a large scalp area following a wide
area removed after discovering a malignant melanoma. That shape is
then reproduced and created inside a mold designed to mimic that
shape. This mold can be filled by electrodepositing the material
into it. In this way, the matrix exactly mimics the mold shape. In
some embodiments, matrices that will become extracellular matrices
and that have a specific shape are used in the creation of a new
organ. Hollow and solid organs can be made. Mixing cells with the
material during electrospraying forms cells within the matrix so
that they do not have to migrate into a matrix.
Methods of Combining Substances with Electroprocessed Materials
[0130] Substances can be combined with the electroprocessed
materials by a variety of means. In some embodiments, the substance
comprises molecules to be released from the electroprocessed
material and is therefore added to or incorporated within the
matrix of electroprocessed material. Substances can be mixed in the
solvent carriers or solutions of materials for electroprocessing.
In this system materials can be mixed with various substances and
directly electroprocessed. The resulting composition comprising an
electroprocessed matrix and substance can be topically applied to a
specific site and the substances released from the material as a
function of the material undergoing breakdown in the surrounding
environment. Substances may also be released-from the
electroprocessed compositions of the present invention through
diffusion.
[0131] The state of the electroprocessed material in relation to
the incorporated substances is dictated and can be controlled by
the chemistry of the system and varies based on the selection of
matrix materials, solvent(s) used, and solubility of the matrix
materials in those solvents. These parameters can be manipulated to
control the release of the substances (or other elements into the
surrounding environment). If substances to be incorporated into the
electroprocessed material are not miscible with the material,
separate solvent reservoirs for the different components can be
used. Mixing in such an embodiment occurs prior to, during, and/or
after deposition on the target, or a combination thereof. It is to
be understood that substances may be entrapped or entangled within
an electroprocessed material, bonded to a material before the
material undergoes electroprocessing, or bound to specific sites
within the matrix material.
[0132] In a variation of this embodiment, the substance is a
particle or aggregate comprising a matrix of compounds or polymers
such as alginate that, in turn, contain one or more compounds that
will be released from the electroprocessed material. Drugs can be
combined with alginate by, for example, combining a drug suspension
or drug particulate in the alginate in the presence of calcium.
Alginate is a carbohydrate that forms aggregates when exposed to
calcium the aggregates can be used to trap drugs. The aggregates
dissolve over time, releasing the trapped substances, such as cells
trapped in alginate. The particles, which are then incorporated
within the larger electroprocessed matrix, are biologically
compatible but relatively stable and will degrade gradually. In
some circumstances, the electroprocessed materials resemble a
string of pearls. This is a physical aspect of the
electroprocessing. If the polymer concentration is low,
electrospraying of beads occurs. As polymer concentration increases
there are some beads and some fibers. A further increase in polymer
concentration leads to predominantly or all fibers. Therefore, the
appearance of the pearls on a string is a transition phase.
[0133] If a drug (for example, penicillin) does not bind or
interact with an electrospun matrix material, the drug can be
entrapped in PGA or PLA pellets or electroaerosoled to produce
pellets in the electrospun material. The pellets or
electroaerosoled droplets containing the drug begin to dissolve
after administration to deliver the entrapped material. Some agents
can be coupled to synthetic, or natural polymer by a covalent bond,
prior to or after spinning.
[0134] In other embodiments, the substance is electroprocessed.
Substances can be electroprocessed from the same orifice as the
materials or from different orifices. Substances can also be
subjected to the same or a different type of electroprocessing as
the material. A molecule can be bonded to the electroprocessed
material directly or through linking to a molecule that has an
affinity for the material. An example of this embodiment involves
bonding polypeptide substances to heparin, which has an affinity
for collagen materials. This embodiment allows release relate to be
controlled by controlling the rate of degradation of the material,
for example by enzymatic or hydrolytic breakdown.
[0135] In other embodiments, the electroprocessed material can
entrap substance during the electrodeposition process. This can be
accomplished by disposing substances in the space between the
source of the electroprocessed stream and the target for the
electroprocessed material. Placing such substances in the space
between the source and target can be accomplished by a number of
methods, including but not limited to, suspending in air or other
gases, dripping, spraying, or electroprocessing the substances. The
substances can be present in that space in, for example,
particulate, aerosol, colloidal, or vapor form. In these
embodiments, the electroprocessed material or matrix will
physically entrap the substances. This embodiment can also be used
to encapsulate larger particles, such as cells, large particles, or
tablets. For example, if a tablet is dropped through the matrix as
it forms, the tablet is surrounded by the matrix. If a small
object, like a cell is dropped through the matrix as it forms or
placed in an aerosol within the matrix, the object may be trapped
between filaments, within filaments or "attached to the outside of
the filaments. For example, by suspending cells in a solution or
within a matrix, the cells can become part of an electrospun matrix
during fabrication of the filaments. Alternatively, encapsulation
can occur by dropping substances onto or through a matrix material
stream as a matrix forms. The cells thus become surrounded by a
matrix of electroprocessed material. These embodiments can be used
to incorporate within a matrix substances that are not soluble
and/or are too-large to form a suspension in the solvent used for
the production of the material. For substances in a mist or vapor
form, controlling distribution and composition of substances in the
space between the source and target can be used to alter the
physical and chemical properties of the electroprocessed material
and the pattern of distribution of the substances in the
electroprocessed material. For all of the foregoing embodiments,
the substances can be placed in the electroprocessed material in
capsules, vesicles, or other containments for subsequent release.
Since the solvent carrier often evaporates in the electroprocessing
technique as the electroprocessed material forms, such as a
filament, substances may be placed in the electroprocessed matrix
and solvent toxicity is greatly reduced or eliminated.
[0136] In embodiments wherein the substance comprises cells, the
cells can, for example, be suspended in a solution or other liquid
that contains the material to be electroprocessed, disposed in the
area between the solutions and target, or delivered to a target or
substrate from a separate source before, during, or after
electroprocessing. Cells can be dripped through the matrix, onto
the matrix as it deposits on the target or suspended within an
aerosol as a delivery system for the cells to the electroprocessed
material. The cells can be delivered in this manner while the
matrix is being formed. As an example, cardiac fibroblasts were
suspended in phosphate-buffered saline (PBS) at a concentration of
approximately one million cells per milliliter. The suspension of
cells was placed within a reservoir of a Paasche air brush. To test
the efficacy of using this type of device to deliver cells, the
cell suspension was initially sprayed onto a 100 mm culture dish.
Some of the cells survived, attached to the dish and spread out
over the substratum. In a second trial, the culture dish was
located further away from the air brush and the experiment was
repeated. Cells were observed on the dish. They appeared to be
flattened by the impact and were partially spread out over the
surface of the substratum. Culture media was added to the dish and
the cells were placed into an incubator. After one hour of culture,
the cells were inspected again, and many were found to have spread
out further over the substratum. These results demonstrate that a
simple airbrush device can be used to place cells into an aerosol
droplet and deliver them on demand to a surface or site of
interest. Cell viability can be improved by restricting this
technique to cells that are resistant to the shear forces produced
in the technique, developing a cell suspension with additives that
cushions the cells or refining the aerosolizing device to produce a
more laminar flow. In addition, directing the cell aerosol into
matrix materials as the matrix is forming in the space between the
target or mandrel and the source(s) of molecules being
electroprocessed produces the effect of cushioning the cells. While
not wanting to be bound by the following statement, it is believed
that the cells will be trapped in the storm of filaments or other
bodies produced by electrospinning or electroprocessing and pulled
onto the mandrel. This situation may be less traumatic to the cells
than directly spraying the cells onto a solid surface.
[0137] In one embodiment, the cells are added either before or at
the same time as the materials or compounds that form
electroprocessed materials are brought together. In this way, the
cells are suspended throughout the three dimensional matrix. In
embodiments in which the electroprocessed material comprises fibrin
formed by combining thrombin and fibrinogen, the cells are
typically included in the mixture that contains the fibrinogen
(whether it is plasma or purified fibrinogen). Whenever materials
comprise two or more separate materials that combine to form a
different material (such as fibrinogen and thrombin) bringing the
materials together immediately prior to insertion into a mold, or
immediately prior to the streaming step in the electrospinning
process helps result in a good distribution of cells in suspension
in the resulting extracellular matrix.
[0138] Cells can be added as the filaments are produced in the
space between the target and polymer source. This is accomplished
by dripping the cells onto the target, dripping the cells into the
matrix as it forms, aerosoling the cells into the matrix or onto
the target or electrospraying the cells into the matrix as it
condenses and forms near or on the grounded target. In another
embodiment, cells are sprayed or dribbled into a forming
electroprocessed material or matrix and thereby trapped as the
electroprocessed material crosses the air gap between the source
solutions and target.
[0139] An alternative method to deliver cells to an
electroprocessed material involves electroaerosol delivery of the
cells. Cells can be deposited by electrostatic spraying at, for
example, 8 kV directly onto standard polystyrene culture dishes,
suggesting that electrostatic cell spraying is a viable approach.
Cardiac fibroblasts in phosphate buffered saline (PBS) have been
electroaerosoled up to a 20 Kv potential difference. In another
example, Schwann cells (rat) were plated on a PS petri dish by
conventional methods after one day. Schwann cells were also
electrosprayed onto a PS petri dish with a metal ground plate
behind the dish at 10 kV after one day. Both samples grew to almost
confluence after one week. The electroaerosol approach provides
some distinct advantages. First, the shear forces produced during
the delivery phase (i.e. the production of the aerosol) appear to
be much less traumatic to the cells. Second, the direction of the
aerosol can be controlled with a high degree of fidelity. In
essence the cell aerosol can be painted onto the surface of
interest. This allows the cell to be targeted to specific sites. In
electroaerosol delivery, cells are suspended in an appropriate
media (e.g. culture media, physiological salts, etc.) and charged
to a voltage, and directed towards a grounded target. This process
is very similar to that used in electroprocessing, particularly
electrospinning. The produces a fine mist of cells trapped within
the droplets as they are produced and directed at the grounded
target.
[0140] Cells can be delivered using aerosol and electroaerosol
techniques onto an electroprocessed material that is forming by an
electroprocessing technique. The electroaerosol of cells can be
delivered in parallel (i.e. alongside) the electroprocessing
material or from a separate site. The cells can be delivered to the
storm of filaments or particles produced within the air gap in the
electrodeposition process or directed at the target. The cells and
elecroprocessed material also can be delivered in an alternating
sequence to the target, i.e. electrodeposit the material, aerosol
the cells, electrodeposit the material, aerosol the cells. This
allows for the discrete layering of the construct in separate
layers. Furthermore, a vapor source can be provided that directs
water onto the mandrel of target used to collect the cells.
Providing this moisture improves cell viability by keeping the
cells from dehydrating during processing. Cells can be added to the
electroprocessed material at any time or from any orientation in
any aerosol strategy. Again the advantage of the process in general
is that collagen, for example, collects in a dried state on the
target mandrel. Accordingly, although some solvents for collagen
may be toxic, they are lost from the system before the filaments
collect on the target.
[0141] Cells can also be trapped within a carrier prior to
producing an aerosol. For example, cells can be encapsulated within
a material like alginate. The encapsulated cells are physically
protected from shear and trauma during processing. Cells delivered
in this form to the electroprocessed material will have higher
viability when sprayed or electrostatically seeded.
[0142] An electroaerosol or otherwise electroprocessed material can
also be delivered directly to an in situ site. For example, an
electroprocessed material can be produced directly onto a skin
wound, with or without substances such as molecules or cells.
Additional cells or materials can then be aerosolized onto or into
the wound site. Other surgical sites can also be amenable the
delivery of materials using various electrodeposition techniques or
combinations thereof of these methods.
[0143] In other embodiments, substances can be applied to the
electroprocessed material after formation, for example by soaking
the electroprocessed material in the substance or by spraying the
substance onto the electroprocessed material.
[0144] Persons skilled in the art will recognize that more than one
method for combining the substances with electroprocessed materials
can be used in a single embodiment or application. Combining
methods can be especially useful in embodiments involving release
of more than one compound or compounds intended to have complex
release kinetics, although such combinations are not limited to
those embodiments.
[0145] Magnetically and electrically active materials can be
electroprocessed, including, for example, preparing conducting
polymer fibers produced by electrospinning. In addition, conducting
polymers can be prepared in-situ in the matrix by, for example,
incorporation of a monomer (e.g., pyrrole) followed by treatment
with polymerization initiator and oxidant (e.g., FeCl.sub.3).
Finally, conducting polymers can be grown in the material after
electroprocessing by using a matrix-coated conductor as the anode
for electrochemical synthesis of, for example, polypyrrole or
polyaniline. Compounds that can form electroprocessed materials can
be added to an aqueous solution of pyrrole or aniline to create a
conducting polymer at the anode with the entrapped electroprocessed
material-forming compounds, which can then be treated with other
compounds to allow formation of the material to occur.
Patterns of Electroprocessed Materials and Substance
Distribution
[0146] Many embodiments of the present invention involve means for
manipulating the pattern or distribution of electroprocessed
materials and/or substances within an electroprocessed material.
For example, an electroprocessing target can also be specifically
charged or grounded along a preselected pattern so that
electroprocessed materials streamed toward the target are directed
into specific directions or distributions on the target or on a
substrate. The electric field can be controlled by a microprocessor
to create a matrix having a desired geometry. The target and the
electroprocessing nozzle or nozzles can be movable with respect to
each other and to the target thereby allowing additional control
over the geometry of the electroprocessed material to be formed. In
embodiments in which substances are electroprocessed, this
manipulation will also allow control of the distribution of
substances within the electroprocessed materials. For example a
matrix can be prepared on a mandrel, and substances from a separate
reservoir can be sprayed, dripped, electroprocessed in a specific
pattern over the existing matrix. This may also be accomplished by
simultaneously electrospraying a matrix from one source and a
substance from another source. In this example the matrix source
may be stationary and the substance source is moved with respect to
the target mandrel.
[0147] Other features that allow establishment of such a pattern
include, but are not limited to, the ability to deposit multiple
layers of the same or different materials, combining different
electroprocessing methods, the use multiple orifices with different
contents for electroprocessing, and the existence of numerous
methods for combining substances with the materials. For example, a
gradient of substances can be created along a electroprocessed
material. In embodiments in which the matrix is shaped into a
cylindrical construct, for example, the gradient can be prepared
along the long axis of a construct (left to right) or the
perpendicular axis (inside to out). This configuration is used to
provide a chemoattractant gradient to guide the movement of cells
within a specified site. Thus, for example, in some embodiments in
which neovascular agents are prepared in a perpendicular gradient
along a collagen-based construct, the agents can be concentrated on
the dorsal surface of a sheet of the material. The ventral side can
be placed against a wound and the higher concentration of
angiogenic materials on the dorsal surface of the construct will
increase the migration of endothelial cells through the electrospun
material. Again, embodiments with complex patterns can use a
microprocessor programmed with the specific parameters to obtain a
specific, preselected electroprocessed pattern of one or more
electroprocessed polymers, optionally with one or more
substances.
Uses for the Compositions of the Present Invention
[0148] Substance Delivery
[0149] One use of the compositions of the present invention is the
delivery of one or more substances to a desired location. In some
embodiments, the electroprocessed materials are used simply to
deliver the materials itself. In other embodiments, the
electroprocessed materials are used to deliver substances that are
contained in the electroprocessed material or that are produced or
released by substances contained in the electroprocessed material.
For example, an electroprocessed material containing cells can be
implanted in a body and used to deliver molecules produced by the
cells after implantation. The present compositions can be used to
deliver substances to an in vivo location, an in vitro location, or
other locations. The present compositions can be administered to
these locations using any method.
[0150] In the field of substance delivery, the compositions of the
present invention have many attributes that allow delivery of
substances using a wide variety of release profiles and release
kinetics. For example, selection of the substance and the method by
which the substance is combined with the electroprocessed material
affects the substance release profile. To the extent that the
substances are not immobilized by the electroprocessed material,
release from the electroprocessed material is a function of
diffusion. An example of such an embodiment is one in which the
substance is sprayed onto the electroprocessed material. To the
extent that the substances are immobilized by the electroprocessed
material, release rate is more closely related to the rate at which
the electroprocessed material degrades. An example of such an
embodiment is one in which the substance is covalently bonded to
the electroprocessed material. For a substance is trapped within an
electrospun aggregate or filament, release kinetics would be
determined by the rate at which the surrounding material degrades
or disintegrates. Still other examples are substances that are
coupled to the electroprocessed material by a light sensitive bond.
Exposing such a bond to light releases the substance from the
electroprocessed material. Conversely, in some embodiments of this
invention, materials can be exposed to light to cause binding of
agents in vivo or in vitro. Combining the compound with the
electroprocessed material in solution, rather than in suspension,
will result in a different pattern of release and thereby provide
yet another level of control for the process. Further, the porosity
of the electroprocessed material can be regulated, which affects
the rate of release of a substance. Enhanced porosity facilitates
release. Substance release is also enhanced by fragmenting or
pulverizing the electroprocessed material. Pulverized material can,
for example be applied to a wound site, ingested or formed into
another shape such as a capsule or a tablet. In embodiments in
which the substance is present in the form of a large particle such
as a tablet encapsulated in the electroprocessed material or a
molecule trapped inside an electroprocessed filament, release is
dictated by a complex interplay of the rate the particles dissolve
or degrade and any breakdown or degradation of the electroprocessed
material structure. In embodiments in which the substance comprises
cells that will express one or more desired compounds, factors that
affect the function and viability of the cells and the timing,
intensity, and duration of expression can all affect the release
kinetics. Chemicals that affect cell function, such as
oligonucleotides, promoters or inhibitors of cell adhesion,
hormones, and growth factors, for example, can be incorporated into
the electroprocessed material and the release of those substances
from the electroprocessed material can provide a means of
controlling expression or other functions of cells in the
electroprocessed material.
[0151] Release kinetics in some embodiments are manipulated by
cross-linking electroprocessed material through any means. In some
embodiments, cross-linking will alter, for example, the rate at
which the electroprocessed material degrades or the rate at which a
compound is released from the electroprocessed material by
increasing structural rigidity and delaying subsequent dissolution
of the electroprocessed material. Electroprocessed materials can be
formed in the presence of cross-linking agents or can be treated
with cross-linking agents after electrodeposition. Any technique
for cross-linking materials may be used as known to one of ordinary
skill in the art Examples of techniques include application of
cross-linking agents and application of certain cross-linking
radiations. Examples of cross-linking agents that work with one or
more proteins include but are not limited to condensing agents such
as aldehydes e.g., glutaraldehyde, carbodiimide EDC (1-ethyl-3(3
dimethyl aminopropyl)), photosensitive materials that cross link
upon exposure to specific wavelengths of light, osmium tetroxide,
carbodiimide hydrochloride, and NHS (n-hydroxysuccinimide), and
Factor XIIa. Ultraviolet radiation is one example of radiation used
to crosslink matrix materials in some embodiments. Natural
materials can be cross-linked with other natural materials. For
example, collagen can be cross-linked and or stabilized by the
addition of fibronectin and or heparin sulfate. For some polymers
heat can be used to alter the matrix and cross link elements of the
matrix by fusing adjacent components of the construct. Polymers may
also be partially solubilized to alter the structure of the
material, for example brief exposure of some synthetics to alcohols
or bases can partially dissolve and anneal adjacent filaments
together. Some polymers may be cross-linked using chemical fusion
or heat fusion techniques. Synthetic polymers generally can be
cross-linked using high energy radiation (e.g., electron beams,
gamma rays). These typically work by the creation of free radicals
on the polymer backbone which then couple, affording cross links.
Backbone free radicals can also be generated via peroxides, azo
compounds, aryl ketones and other radical-producing compounds in
the presence of heat or light. Reduction-oxidation reactions that
produce radicals (e.g., peroxides in the presence of transition
metal salts) can also be used. In many cases, functional groups on
polymer backbones or side chains can be reacted to form
cross-links. For example, polysaccharides can be treated with
diacylchlorides to form diester cross-links. Cross-linking may also
occur after application of a matrix where desirable. For example, a
matrix applied to a wound may be cross-linked after application to
enhance adhesion of the matrix to the wound.
[0152] The release kinetics of the substance is also controlled by
manipulating the physical and chemical composition of the
electroprocessed material. For example, small fibers of PGA are
more susceptible to hydrolysis than larger diameter fibers of PGA.
An agent delivered within an electroprocessed material composed of
smaller PGA fibers is released more quickly than when prepared
within a material composed of larger diameter PGA fibers.
[0153] In some embodiments substances such as peptides can be
released in a controlled manner in a localized domain. Examples
include embodiments in which the substance is chemically or
covalently bonded to the electroprocessed material. The formation
of peptide gradients is a critical regulatory component of many
biological processes, for example in neovasculogenesis. In surgical
applications, anti-vascular peptides or anti-sense oligonucleotides
can be incorporated into an electroprocessed material that is then
wrapped around or placed within a tumor that is inaccessible to
conventional treatments to allow for localized release and effect.
Release of the anti-vascular substances suppresses tumor growth.
Antisense oligonucleotides can be released from the construct into
the tumor and used to suppress the expression gene sequences of
interest. In another example anti-sense sequences directed against
gene sequences that control proliferation can be delivered within
an electroprocessed matrix coated stent. The stretch normally
associated with the placement of the stent initiates smooth muscle
cell proliferation, and anti-sense sequences designed to suppress
cell division reduce the deleterious effects of the smooth muscle
cell proliferation associated with the procedure. In another
embodiments, the electroprocessed material delivers sense and
antisense oligonucleotides to promote or to inhibit localized cell
function for a period of time. For example, an antisense
oligonucleotide is released from an electroprocessed material to
suppress the expression of a deleterious enzyme in a wound.
Examples of such enzymes are matrix metalloproteinases (MMPs),
which are often overexpressed in chronic wounds. In another
example, the electroprocessed material applied to a wound releases
plasmids that contain nucleotide sequences coding for tissue
inhibitors of metalloproteinases (TIMPs). Cells in the wound will
express TIMPs, resulting in local delivery of TIMPs that will
inhibit MMP function.
[0154] Physical processing of the formed electroprocessed material
is another way to manipulate release kinetics. In some embodiments,
mechanical forces, such as compression, applied to an
electroprocessed material hasten the breakdown of the matrix by
altering the crystalline structure of the material. Structure of
the matrix is thus another parameter that can be manipulated to
affect release kinetics. Polyurethanes and other elastic materials
such as poly(ethylene-co-vinyl acetate), silicones, and polydienes
(e.g., polyisoprene), polycaprolactone, polyglycolic acid and
related polymers are examples of materials whose release rate can
be altered by mechanical strain.
[0155] Release kinetics can also be controlled by preparing
laminates comprising layers of electroprocessed materials with
different properties and substances. For example, layered
structures composed of alternating electroprocessed materials can
be prepared by sequentially electroprocessing different materials
onto a target. The outer layers can, for example, be tailored to
dissolve faster or slower than respect the inner layers. Multiple
agents can be delivered by this method, optionally at different
release rates. Layers can be tailored to provide a complex,
multi-kinetic release profile of a single agent over time. Using
combinations of the foregoing can provide for release of multiple
substances released, each with a complex profile.
[0156] Suspending a substance in particles that are incorporated in
the electroprocessed material provides another means for
controlling release profile. Selection of the composition of these
smaller particle matrices provides yet another way to control the
release of compounds from the electroprocessed material. The
release profile can be tailored by the composition of the material
used in the process.
[0157] Embodiments also exist in which the substances are contained
in liposomes or other vesicles in the electroprocessed matrix.
Vesicles are prepared that will release one or more compounds when
placed in fluids at a specific pH range, temperature range, or
ionic concentration. Methods for preparing such vesicles are known
to persons of skill in the art. The electroprocessed material can
be delivered to a site of interest immediately or is stored either
dry or at a pH at which release will not occur, and then delivered
to a location containing liquids that have a pH at which release
will occur. An example of this embodiment is an electroprocessed
material containing vesicles that will release a desired compound
at the pH of blood or other fluids released from a wound. The
matrix is placed over a wound and releases fluids upon discharge of
fluids from the wound.
[0158] Incorporating constituents that are magnetically sensitive
or electrically sensitive into the electroprocessed material
provides another means of controlling the release profile. A
magnetic or electric field can then be subsequently applied to some
or all of the matrix to alter the shape, porosity and/or density of
the electroprocessed material. For example, a field can stimulate
movement or conformational changes in the matrix due to the
movement of magnetically or electrically sensitive particles. Such
movement can affect the release of compounds from the
electroprocessed material. For example, altering the conformation
of the material can increase or decrease the extent to which the
material is favorable for compound release.
[0159] In some embodiments, magnetic or electrically sensitive
constituents that have been processed or co-processed with an
electroprocessed material can be implanted subdermally to allow
delivery of a drug over a long interval of time. By passing a
magnetic field or an electrical field across the material, drug
release is induced. The electroprocessed material structure is
stable and does not substantially change without electromagnetic
stimulation. Such embodiments provide controlled drug delivery over
a long period of time. For example, an electroprocessed material
that has magnetic or electrical properties and insulin can be
fabricated and placed subdermally in an inconspicuous site. By
passing a magnetic field or an electrical field across the
composition, insulin release can be induced. A similar strategy may
be used to release compounds from a construct that has light
sensitive elements, exposing these materials to light will either
cause the material itself to breakdown and or cause the release of
substances that are bound to the electroprocessed material by the
light sensitive moiety.
[0160] In other embodiments, the substances comprise vesicles
encapsulated within the electroprocessed material along with
electrical or magnetic materials. The vesicles contain a compound
to be released from the vesicles. Placing an electrical or magnetic
field across the electroprocessed material causes the compounds
within the vesicles can be released by, for example, deforming the
vesicles to the point of rupture or by changing the permeability
(in some cases reversibly) of the vesicle wall. Examples of these
embodiments include transfection agents, such as liposomes, that
contain nucleic acids that enhance the efficiency of the process of
gene delivery to the cell.
[0161] In other embodiments, the composition comprising an
electroprocessed material and substance is used as a transdermal
patch for localized delivery of medication, or of a component of
such a patch. In some of these embodiments, electrically conductive
materials are incorporated into such a composition, which is then
used as a component of an iontophoresis system in which one or more
substances is delivered in response to the passage of electric
current. Electrically conductive materials can have a direct
healing effect on bone injuries. For example placing a small
electric current across a fracture site promotes healing. An
electroprocessed bone mimetic that conducts or produces current can
be made and placed within a fracture. The addition of the
electrical current will promote healing at a rate that is faster
than the addition of the electroprocessed composition alone.
[0162] In other embodiments, an electroprocessed material or a
portion thereof containing electromagnetic properties is stimulated
by exposure to a magnet to move and thereby to apply or to release
physical pressure to a pressure sensitive capsule or other
enclosure that contains molecules to be released from the material.
Depending on the embodiment, the movement will affect the release
relate of the encapsulated molecules.
[0163] Response of the composition to electric and magnetic fields
can be regulated by features such as the composition of the
electroprocessed material, size of the filaments, and the amount of
conductive material added. Electromechanical response from
polyaniline is the result of doping-induced volume changes, whereas
ion gradients leading osmotic pressure gradients are responsible
for field-induced deformation in ionic gels such as
poly(2-acrylamido-2-methyl propanesulfonicacid). In each case, ion
transport kinetics dominates the response, and facile transport is
observed with the small fibers. Gel swelling and shrinking kinetics
have been shown to be proportional to the square of the diameter of
a gel fiber. Electromechanical response times of fiber bundles of
less than 0.1s, are possible in the regime of typical muscle.
[0164] Embodiments involving delivery of molecules produced by
cells provide many means by which rejection and immune response to
cells can be avoided. Embodiments using cells from a recipient thus
avoid the problems associated with rejection and inflammatory and
immunological response to the cells. In embodiments in which cells
from an organism other than the recipient are used, the matrix can
sequester the cells from immune surveillance by the recipient's
immune system. By controlling parameters such as the pore size of
the electroprocessed material or matrix, nutritive support to the
cells trapped in the matrix can be permitted while the cells are
protected from detection and response by the recipient's immune
system. As an example, pancreatic islet cells that manufacture
insulin collected from a donor can be encapsulated in an
electroprocessed matrix and implanted in a recipient who cannot
make insulin. Such an implant can be placed, for example,
subdermally, within the liver, or intramuscularly. For some immune
responses permanent sequestration from the host system may not be
necessary. The electroprocessed material can be designed to shield
the implanted material for a given length of time and then begin to
breakdown. In still other embodiments, bacteria or other microbial
agents engineered to manufacture the desired compound can be used.
This embodiment provides the advantages of using cells that are
more easily manipulated than cells from the recipient or a donor.
Again, the electroprocessed material can serve to shield the
bacteria from immune response in this embodiment. The advantage of
using a bacteria carrier is that these microbes are more easily
manipulated to express a wide variety of products. Embodiments in
which cells are transiently transfected allow for expression to be
limited to a defined period. Transient genetic engineering allows
cells to revert to their original state in embodiments in which
such reversion is desired to minimize the risks of
complications.
[0165] In some embodiments, cells are genetically engineered such
that the expression of a specific gene may be promoted or inhibited
through various means known in the art. For example, a tetracycline
sensitive promoter can be engineered into a gene sequence. That
sequence is not expressed until the tetracycline is present. Cell
markers or bacterial markers can also be used to identify the
inserted material. For example, green fluorescent proteins placed
within an engineered genetic material glow green when expressed.
Embodiments using this feature allow verification of the viability
of the cells, bacteria, or gene sequences in a matrix. The
visibility of such a marker also assists in recovering an implanted
electroprocessed composition.
[0166] Although the present invention provides versatility in
release kinetics, embodiments also exist in which one or more
substances are not released at all from the electroprocessed
material. Substances may perform a function at a desired site. For
example, in some embodiments, antibodies for a specific molecule
are immobilized on an electroprocessed matrix and the composition
is placed at a desired site. In this embodiment, the antibodies
acts to bind the molecules in the vicinity of the composition. This
embodiment is useful for isolating molecules that bind to an
antibody. Another example is an electroprocessed matrix containing
immobilized substrates that will bind irreversibly to an
undesirable enzyme and thereby inactivate the enzyme.
[0167] The compositions of the present invention may be combined
with pharmaceutically or cosmetically acceptable carriers and
administered as compositions in vitro or in vivo. Forms of
administration include but are not limited to injections,
solutions, creams, gels, implants, pumps, ointments, emulsions,
suspensions, microspheres, particles, microparticles,
nanoparticles, liposomes, pastes, patches, tablets, transdermal
delivery devices, sprays, aerosols, or other means familiar to one
of ordinary skill in the art. Such pharmaceutically or cosmetically
acceptable carriers are commonly known to one of ordinary skill in
the art. Pharmaceutical formulations of the present invention can
be prepared by procedures known in the art using well known and
readily available ingredients. For example, the compounds can be
formulated with common excipients, diluents, or carriers, and
formed into tablets, capsules, suspensions, powders, and the like.
Examples of excipients, diluents, and carriers that are suitable
for such formulations include the following: fillers and extenders
(e.g., starch, sugars, mannitol, and silicic derivatives); binding
agents (e.g., carboxymethyl cellulose and other cellulose
derivatives, alginates, gelatin, and polyvinyl-pyrrolidone);
moisturizing agents (e.g., glycerol); disintegrating agents (e.g.,
calcium carbonate and sodium bicarbonate); agents for retarding
dissolution (e.g., paraffin); resorption accelerators (e.g.,
quaternary ammonium compounds); surface active agents (e.g., cetyl
alcohol, glycerol monostearate); adsorptive carriers (e.g., kaolin
and bentonite); emulsifiers; preservatives; sweeteners;
stabilizers; coloring agents; perfuming agents; flavoring agents;
lubricants (e.g., talc, calcium and magnesium stearate); solid
polyethyl glycols; and mixtures thereof.
[0168] The terms "pharmaceutically or cosmetically acceptable
carrier" or "pharmaceutically or cosmetically acceptable vehicle"
are used herein to mean, without limitations, any liquid, solid or
semi-solid, including but not limited to water or saline, a gel,
cream, salve, solvent, diluent, fluid ointment base, ointment,
paste, implant, liposome, micelle, giant micelle, and the like,
which is suitable for use in contact with living animal or human
tissue without causing adverse physiological or cosmetic responses,
and which does not interact with the other components of the
composition in a deleterious manner. Other pharmaceutically or
cosmetically acceptable carriers or vehicles known to one of skill
in the art may be employed to make compositions for delivering the
molecules of the present invention.
[0169] The formulations can be so constituted that they release the
active ingredient only or preferably in a particular location,
possibly over a period of time. Such combinations provide yet a
further mechanism for controlling release kinetics. The coatings,
envelopes, and protective matrices may be made, for example, from
polymeric substances or waxes.
[0170] Methods of in vivo administration of the compositions of the
present invention, or of formulations comprising such compositions
and other materials such as carriers of the present invention that
are particularly suitable for various forms include, but are not
limited to, oral administration (e.g. buccal- or sublingual
administration), anal administration, rectal administration,
administration as a suppository, topical application, aerosol
application, inhalation, intraperitoneal administration,
intravenous administration, transdermal administration, intradermal
administration, subdermal administration, intramuscular
administration, intrauterine administration, vaginal
administration, administration into a body cavity, surgical
administration at the location of a tumor or internal injury,
administration into the lumen or parenchyma of an organ, and
parenteral administration. Techniques useful in the various forms
of administrations above include but are not limited to, topical
application, ingestion, surgical administration, injections,
sprays, transdermal delivery devices, osmotic pumps,
electrodepositing directly on a desired site, or other means
familiar to one of ordinary skill in the art. Sites of application
can be external, such as on the epidermis, or internal, for example
a gastric ulcer, a surgical field, or elsewhere.
[0171] The compositions of the present invention can be applied in
the form of creams, gels, solutions, suspensions, liposomes,
particles, or other means known to one of skill in the art of
formulation and delivery of therapeutic and cosmetic compounds.
Ultrafine particle sizes of electroprocessed materials can be used
for inhalation delivery of therapeutics. Some examples of
appropriate formulations for subcutaneous administration include
but are not limited to implants, depot, needles, capsules, and
osmotic pumps. Some examples of appropriate formulations for
vaginal administration include but are not limited to creams and
rings. Some examples of appropriate formulations for oral
administration include but are not limited to: pills, liquids,
syrups, and suspensions. Some examples of appropriate formulations
for transdermal administration include but are not limited to gels,
creams, pastes, patches, sprays, and gels. Some examples of
appropriate delivery mechanisms for subcutaneous administration
include but are not limited to implants, depots, needles, capsules,
and osmotic pumps. Formulations suitable for parenteral
administration include but are not limited to aqueous and
non-aqueous sterile injection solutions which may contain
anti-oxidants, buffers, bacteriostats and solutes which render the
formulation isotonic with the blood of the intended recipient; and
aqueous and non-aqueous sterile suspensions which may include
suspending agents and thickening agents. Extemporaneous injection
solutions and suspensions may be prepared from sterile powders,
granules and tablets commonly used by one of ordinary skill in the
art.
[0172] Embodiments in which the compositions of the invention are
combined with, for example, one or more "pharmaceutically or
cosmetically acceptable carriers" or excipients may conveniently be
presented in unit dosage form and may be prepared by conventional
pharmaceutical techniques. Such techniques include the step of
bringing into association the compositions containing the active
ingredient and the pharmaceutical carrier(s) or excipient(s). In
general, the formulations are prepared by uniformly and intimately
bringing into association the active ingredient with liquid
carriers. Preferred unit dosage formulations are those containing a
dose or unit, or an appropriate fraction thereof, of the
administered ingredient. It should be understood that in addition
to the ingredients particularly mentioned above, formulations
comprising the compositions of the present invention may include
other agents commonly used by one of ordinary skill in the art. The
volume of administration will vary depending on the route of
administration. For example, intramuscular injections may range in
volume from about 0.1 ml to 1.0 ml.
[0173] The compositions of the present invention may be
administered to persons or animals to provide substances in any
dose range that will produce desired physiological or
pharmacological results. Dosage will depend upon the substance or
substances administered, the therapeutic endpoint desired, the
desired effective concentration at the site of action or in a body
fluid, and the type of administration. Information regarding
appropriate doses of substances are known to persons of
ordinary-skill in the art and may be found in references such as L.
S. Goodman and A. Gilman, eds, The Pharmacological Basis of
Therapeutics, Macmillan Publishing, New York, and Katzung, Basic
& Clinical Pharmacology, Appleton & Lang, Norwalk, Conn.,
(6.sup.th Ed. 1995). One desirable dosage range is 0.01 .mu.g to
100 mg. Another desirable dosage range is 0.1 .mu.g to 50 mg.
Another desirable dosage range is 0.1 pg to 1.0 .mu.g. A clinician
skilled in the art of the desired therapy may chose specific
dosages and dose ranges, and frequency of administration, as
required by the circumstances and the substances to be
administered. For example, a clinician skilled in the art of
hormone replacement therapy may chose specific dosages and dose
ranges, and frequency of administration, for a substance such as
progesterone, to be administered in combination with the estrogenic
and estrogenic modulatory molecules as required by the
circumstances. For example, progesterone, and other progestins
known to one of skill in the art may be administered in amounts
ranging from about 50 .mu.g to 300 mg, preferably 100 .mu.g to 200
mg, more preferably 1 mg to 100 mg. Specific dosages and
combinations of dosages of estrogenic and estrogenic modulatory
molecules and progestins will depend on the route and frequency of
administration, and also on the condition to be treated. For
example, when the composition is formulated for oral
administration, preferably in the form of a dosage unit such as a
capsule, each dosage unit may preferably contain 1 .mu.g to 5 mg of
estrogenic and estrogenic modulatory molecules and 50 .mu.g to 300
mg of progesterone. U.S. Pat. No. 4,900,734 provides additional
examples of acceptable dose combinations of estrogenic molecules
and progestins.
Other Uses Involving Electrically or Magnetically Active
Constituents
[0174] The compositions of the present invention have a number of
additional uses aside from substance delivery. Embodiments exist in
which the incorporation of electrically or magnetically active
constituents in the electroprocessed material allows the
electroprocessed material to move rhythmically in response to an
oscillating electric or magnetic field. Such an electroprocessed
material can be used, for example; in a left ventricular assist
device by providing a pumping action or a ventricular massage to a
heart patent. Oscillations can be accomplished by passive movement
of a magnetic or electric field with respect to the conductive
material, or vice versa. By manipulating material selection, the
electroprocessed material can be designed to remain in place
permanently or to dissolve over time, eliminating the need for
surgery to recover the device once the heart had recovered
sufficiently.
[0175] Embodiments also exist in which an implanted
electroprocessed material is used to convey an electric charge or
current to tissue. For example, electrically active constituents
can be electrically stimulated to promote neural ingrowth, stem
cell differentiation, or contraction of engineered muscle, or to
promote the formation of bone in orthopedic applications in which
electroprocessed material is used as a carrier to reconstruct bone.
In one embodiment, for example, an electroprocessed material is
applied to a bone injury site and used to apply an electric current
to the material to facilitate and to promote healing. The
application of a small electric current to an injured bone is known
to accelerate healing or promote the healing of bone injuries.
[0176] In other embodiments involving magnetically reactive
materials, a magnetic field is used to position an electroprocessed
material containing substances by relatively non-invasive means,
for example by directing the movement of the material within the
peritoneum. In other embodiments, a composition containing
electrically active compounds is used to produce electric
field-driven cell migration. This approach accelerates the healing
process and minimize the risk of bacterial colonization. In one
example, an orthopedic implant is coated with a very thin (<100
microns) layer of an electrically active polymer. With a very thin
electrode attached to the coating, upon post-implantation, an
electric field can be applied via an external electrode such that
the electric field-driven cell migration is towards the implant
surface. The direction can be reversed if so desired. Field
orientation depends on the geometry of the implant and external
electrode.
Use in Gene Therapy
[0177] Compositions of the present invention are also useful for
testing and applying various gene therapies. By working with the
compositions in vitro, different types of gene therapy and
manipulation can be achieved by inserting preselected DNA in
suspensions of cells, materials, etc. For example, nonviral
techniques such as electroporation are used to treat cultured cells
prior to insertion into the matrix of the present invention. In
other embodiments, cells are treated within the matrix before the
composition is inserted into a recipient. In vitro gene transfer
avoids the exposure of a recipient to viral products, reduces risk
of inflammation from residual viral particles and avoids the
potential for germ cell line viral incorporation. It avoids the
problem of finding or engineering viral coats large enough to
accept large genes such as the one for Factor VIII (anti-hemophilic
factor). However, in vivo gene therapy is accomplished in some
embodiments by, for example, incorporating DNA into the
electroprocessed material as it is created through the
electroprocessing techniques of the present invention, whereby some
DNA will be incorporated into the in vivo cells in contact with the
composition after application of the composition to the recipient.
This is especially true of small gene sequences, such as antisense
oligonucleotides.
Use of an Electroprocessed Composition as Tissue or Organ
Replacement
[0178] The ability to combine cells in an electroprocessed material
provides the ability to use the compositions of the present
invention to build tissue, organs, or organ-like tissue. Cells
included in such tissues or organs can include cells that serve a
function of delivering a substance, seeded cells that will provide
the beginnings of replacement tissues or both. Many types of cells
can be used to create tissue or organs. Stem cells, committed stem
cells, and/or differentiated cells are used in various embodiments.
Also, depending on the type of tissue or organ being made, specific
types of committed stem cells are used. For instance, myoblast
cells are used to build various muscle structures, neuroblasts are
employed to build nerves, and osteoblasts are chosen to build bone.
Examples of stem cells used in these embodiments include but are
not limited to embryonic stem cells, bone marrow stem cells and
umbilical cord stem cells used to make organs or organ-like tissue
such as livers, kidneys, etc. Examples of tissue embodiments that
use differentiated cells include fibroblasts in a matrix used for a
patch, for example a hernia patch, endothelial cells for skin,
osteoblasts for bone, and differentiated cells like cadaver donor
pancreatic islet cells for a delivery device to place these cells
in a specific site, for example the liver. In some embodiments the
shape of the electroprocessed composition helps send signals to the
cells to grow and reproduce in a specific type of desired way.
Other substances (for example, differentiation inducers) can be
added to the electroprocessed matrix to promote specific types of
cell growth. Further, different mixtures of cell types are
incorporated into the composition in some embodiments.
[0179] In certain disease states, organs are scarred to the point
of being dysfunctional. A classic example is cirrhosis. In
cirrhosis, normal hepatocytes are trapped in fibrous bands of scar
tissue. In one embodiment of the invention, the liver is biopsied,
viable liver cells are obtained then cultured in an
electroprocessed matrix, and re-implanted in the patient as a
bridge to or replacement for routine liver transplantations.
[0180] Mixing of committed cell lines in a three dimensional
electroprocessed matrix can be used to produce structures that
mimic complex organs. For example, by growing glucagon secreting
cells, insulin secreting cells, somatostatin secreting cells,
and/or pancreatic polypeptide secreting cells, or combinations
thereof, in separate cultures, and then mixing them together with
electroprocessed materials through electroprocessing, an artificial
pancreatic islet is created. These structures are then placed under
the skin, retroperitoneally, intrahepatically or in other desirable
locations, as implantable, long-term treatments for diabetes.
[0181] In other examples, hormone-producing cells are used, for
example, to replace anterior pituitary cells to affect synthesis
and secretion of growth hormone secretion, luteinizing hormone,
follicle stimulating hormone, prolactin and thyroid stimulating
hormone, among others. Gonadal cells, such as Leydig cells and
follicular cells are employed to supplement testosterone or
estrogen levels. Specially designed combinations are useful in
hormone replacement therapy in post and perimenopausal women, or in
men following decline in endogenous testosterone secretion.
Dopamine-producing neurons are used and implanted in a matrix to
supplement defective or damaged dopamine cells in the substantia
nigra. In some embodiments, stem cells from the recipient or a
donor can be mixed with slightly damaged cells, for example
pancreatic islet cells, or hepatocytes, and placed in an
electroprocessed matrix and later harvested to control the
differentiation of the stem cells into a desired cell type. This
procedure is performed in vitro or in vivo. The newly formed
differentiated cells are introduced into the patient.
[0182] The ability to use electroprocessed materials and matrices
to bioengineer tissue or organs creates a wide variety of
bioengineered tissue replacement applications. Examples of
bioengineered components include, but are not limited to, skeletal
muscle, cardiac muscle, nerve guides, brain constructs as a filler
for damaged/removed areas of the brain that are lost during
accident or disease, a filler for other missing tissues, cartilage
scaffoldings, sheets for cosmetic repairs, skin (sheets with cells
added to make a skin equivalent), vascular grafts and components
thereof, and sheets for topical applications (skin covering but no
additional cells, just a patch). In some embodiments, such matrices
are combined with drug and substance delivery electroprocessed
matrices of the present invention in ways that will improve the
function of the implant. For example, antibiotics,
anti-inflammatories, local anesthetics or combinations thereof, can
be added to the matrix of a bioengineered organ to speed the
healing process and reduce discomfort.
[0183] One method or preparing implants of the present invention is
use of a bioreactor. There are several kinds of commercially
available bioreactors, devices designed to provide a low-shear,
high nutrient perfusion environment. Until recently, most of the
available bioreactors maintained cells in suspension and delivered
nutrients and oxygen by sparging, through the use of impellers, or
other means of stirring. The RCCS bioreactor (Synthecon) is a
rotating wall bioreactor. It consists of a small inner cylinder,
the substrate for the electrospinning process, positioned inside a
larger outer cylinder. Although the electrospun or electroaerosol
matrix can be fabricated on the inner cylinder, other locations
within the bioreactor also can be used for placement of a matrix
for seeding. The gap between the inner and outer cylinders serves
as the culture vessel space for cells. Culture medium is oxygenated
via an external hydrophobic membrane. The low shear environment of
the Synthecon RCCS bioreactor promotes cell-cell and
cell-extracellular matrix (ECM) interactions without the damage or
"washing away" of nutrients that occurs with active stirring or
sparging. Typically, the RCCS device is operated at rotation rates
of 8 up to 60 RPM, as required to maintain cells in suspension, and
at less than 8 RPM (preferably 2-3 RPM) for cultures immobilized
along the center shaft of the vessel. The Synthecon bioreactor can
be used in a standard tissue culture incubator. These values for
spin rates and other parameters can be varied depending on the
specific tissue created.
[0184] Electroprocessed materials, such as matrices, are useful in
formation of prostheses. One application of the electroprocessed
matrices is in the formation of medium and small diameter vascular
prostheses. Some preferred materials for this embodiment are
collagen and elastin, especially collagen type I and collagen type
III. Some examples include, but are not limited to coronary vessels
for bypass or graft, femoral artery, popliteal artery, brachial
artery, tibial artery, radial artery or corresponding veins. The
electroprocessed material is useful especially when combined with
endothelial cells on the inside of the vascular prosthesis, and
smooth muscle cells, for example a collagen tube, and also when
combined with fibroblasts on the outside of the collagen tube. More
complicated shapes including tapered and/or branched vessels can
also be constructed. A different-shaped mandrel is necessary to
wind the large fibers around or to orient the
electrospun/electroaerosol polymer.
[0185] Combination of electroprocessed matrix materials and wound
polymer fibers can provide optimal growth conditions for cells. The
polymer forms a basic structural matrix and the electroprocessed
matrix is used to deliver the cells. This facilitates cell
attachment onto the structural matrix. Furthermore the stress in
the polymer also orients fibers in the matrix providing further
spatial cues for the cells.
[0186] In an alternative fabrication strategy, a cylindrical
construct is electrospun onto a suitable target, for example a
cylindrical mandrel. Other shapes can be used if desirable based
upon the shape of the site into which the implant will be placed.
Matrices in this embodiment are composed, for example, of
electroprocessed fibrinogen/fibrin (for example to promote
neovascularization, cellular integration and infiltration from the
surrounding tissue), electroprocessed collagen (to promote cell
infiltration and lend mechanical integrity), and other components,
for example PGA, PLA, and PGA-PLA blends, PEO, PVA or other blends.
The relative ratio of the different components of this construct is
tailored to specific applications (e.g. more fibrin, less collagen
for enhanced vascularization in a skin graft). To fabricate a
cylindrical muscle the construct is filled with muscle or stem
cells or other cell type and the distal ends of the electrospun
constructs are sutured or sealed shut. In some embodiments, cells
are mixed with various matrix materials to enhance their
distribution within the construct. For example, the cells can be
mixed with electroprocessed fibrin or collagen prior to insertion
into the construct. The objective of this strategy is to provide
additional mechanical support to the construct and provide the
cells with a three dimensional matrix within the construct to
promote growth. This also helps to maintain the cells in an even
distribution within the construct. This method can be used to
enhance the alignment of the cells within the construct. This
filling material can be extruded directly into the cylindrical
construct, as the filling is extruded, alignment occurs. Mixing
endothelial cells with the other cells inserted into the construct
(or other cell types) can be done to accelerate neovascularization.
Another method to accomplish this objective is to electrodeposit
endothelial cells directly into the electroprocessed
collagen-matrix that aids in formation of the cylindrical sheath.
The alignment of the fibers within the electroprocessed matrix that
comprises the construct are optionally controlled by controlling
the relative movement of the target and source solution with
respect to one another. Other cell types, such as tendon
fibroblasts, are optionally electrospun into or onto the outer
surface of the construct to enhance the formation of the outer
connective tissue sheath that forms the construct.
[0187] In another example a sheet of electroprocessed material is
prepared, rolled into a cylinder and inserted into an
electroprocessed cylinder. The construct is filled with cells as
described above, sutured shut and placed in a bioreactor or
directly in situ. By aligning the fibrils of the electrospun sheet
of material in parallel with the long axis of the outer cylinder a
muscle-like, electroprocessed composition is produced. Cells in
contact with the fibrils that are arrayed along the long axis of
the sheet spread in parallel with the fibrils of the sheet, forming
a muscle construct of cells arrayed and layered in a pattern of
organization similar to that present in vivo. The cylindrical
tissue construct is then implanted or placed within a RCCS
bioreactor. Rates of rotation to maintain this type of construct in
suspension range from 4-20 rpm, depending upon the over mass of the
tissue and the specific materials used to fabricate the outer
cylinder.
[0188] Vascularization of the engineered tissue containing
electroprocessed matrix material will occur in situ several days
after surgery. In some embodiments, neovascularization of an
engineered construct containing electroprocessed material is
enhanced by mixing endothelial cells into the construct during
fabrication. Another alternative for supplying engineered tissue
containing electroprocessed material with a vascular supply is to
temporarily transplant the tissue into the omentum. The omentum has
an extensive and rich vascular supply that can be used like a
living incubator for the support of engineered tissue. The
engineered tissue is removed from a bioreactor, wrapped in the
omentum and supported by the diffusion of nutrients and oxygen from
the surrounding tissue in the omentum. Alternatively, or in
addition to this approach, engineered tissue is connected directly
to the endogenous vascular supply of the omentum. A blood vessel
can be partially perforated or cut or left dissected free of the
omentum. The engineered tissue containing electroprocessed
collagen, fibrin, or other materials, depending upon the construct,
is wrapped around the vessel. The engineered tissue is supported by
nutrients leaking from the perforated vessel or by the simple
diffusion of nutrients if the vessel is left intact. Regardless of
strategy, the engineered tissue is surrounded by the omentum and
its rich vascular supply.
[0189] Tissue containing electroprocessed material can be
engineered with an endogenous vascular system. This vascular system
can be composed of artificial vessels or blood vessels excised from
a donor site on the transplant recipient The engineered tissue
containing electroprocessed matrix material is then assembled
around the vessel. By enveloping such a vessel with the tissue
during or after assembly of the engineered tissue, the engineered
tissue has a vessel that can be attached to the vascular system of
the recipient. In this example, a vessel in the omentum, or other
tissue is cut, and the vessel of the engineered tissue is connected
to the two free ends of the omental vessel. Blood passes from the
omental vessel into the vascular system of the engineered tissue,
through the tissue and drains back into the omentum vessel. By
wrapping the tissue in the omentum and connecting it to an omental
blood vessel, the engineered tissue is supported by the diffusion
of nutrients from the omentum and the vessel incorporated into the
tissue during its fabrication. After a suitable period of time the
tissue is removed from the omentum and placed in the correct site
in the recipient. By using this strategy the engineered tissue
containing electroprocessed material is supported in a nutrient
rich environment during the first several days following removal
from the bioreactor. The environment of the omentum also promotes
the formation of new blood vessels in implanted tissue. This
omental incubator strategy can be combined with the other
strategies such as combining angiogenic factors in the matrix
material during electroprocessing. Several options are available.
First, the implants can be seeded with angioblasts and/or
endothelial cells to accelerate the formation of vascular elements
once the engineered tissue is placed in situ. Second, angiogenic
peptides can be introduced into the engineered tissue via an
osmotic pump. The use of an osmotic pump permits delivery of
peptides or, as noted, angiogenic peptides or growth factors
directly to the site of interest in a biologically efficient and
cost-effective manner. VEGF delivered to ischemic hind limbs of
rabbits accelerated capillary bed growth, increased vascular
branching and improved muscular performance with respect to
ischemic controls. An alternative approach is to seed fully
differentiated tissue constructs containing electroprocessed matrix
material with additional endothelial cells and or angioblasts
shortly before they are implanted in situ.
[0190] In some embodiments, the stem cells or other cells used to
construct the implant are isolated from the subject, or other
compatible donor requiring tissue reconstruction. This provides the
advantage of using cells that will not induce an immune response,
because they originated with the subject (autologous tissue)
requiring the reconstruction. Relatively small biopsies can be used
to obtain a sufficient number of cells to construct the implant.
This minimizes functional deficits and damage to endogenous tissues
that serve as the donor site for the cells.
[0191] In some embodiments, the matrices of the present invention
include substances in the matrix that will improve the performance
of the implanted electroprocessed matrix. Examples of substances
that can be used include peptide growth factors, antibiotics,
and/or anti-rejection drugs. Alternatively, cells that are
engineered to manufacture desired compounds can be included. The
entire construct is, for example, cultured in a bioreactor or
conventional culture or placed directly in vivo. For example,
neovascularization can be stimulated by angiogenic and
growth-promoting factors, administered, as peptides, proteins or as
gene therapy. Angiogenic agents can be incorporated into the
electroprocessed matrix. Nerve growth factors can be electrospun
into the matrix to promote growth or neurons into the matrix and
tissue. In a degradable matrix, the gradual degradation/breakdown
of the matrix will release these factors and accelerate growth of
desired tissues.
[0192] Electroprocessed matrices can also be used in connection
with other matrix building processes. In other words, an extruded
tube can have an outside layer electrospun onto it wherein the
different layers complement each other and provide an appropriate
matrix to promote a specific type of cell growth. As an example, a
vascular graft comprised primarily of a collagen tube can have an
electrospun layer of both other materials such as collagen or
fibrin and cells added to promote the acceptability of the graft in
a particular recipient. A second example is an in vitro skin
preparation formed by growing fibroblasts in one layer, covering
the first layer with electroprocessed collagen, and then growing a
second layer composed of epidermal cells in the fibrin matrix. This
layering technique can be used to make a variety of tissues.
Stability and Storage of the Electroprocessed Compositions
[0193] The stability of the compositions of the present invention
comprising electroprocessed materials combined with substances also
allows for long term storage of the compositions between formation
and use. Stability allows greater flexibility for the user in
embodiments in which a drug or other substance is applied after
formation of the electroprocessed material, for example by soaking
and spraying. A formed electroprocessed matrix can be fabricated
and stored, and then the exact substance composition to be
delivered to an individual patient can be prepared and tailored to
a specific need shortly before implantation or application. This
feature allows users greater flexibility in both treatment options
and inventory management. Many electroprocessed materials are dry
once they are spun, essentially dehydrated, thereby facilitating
storage in a dry or frozen state. Further, the electroprocessed
compositions are substantially sterile upon completion, thereby
providing an additional advantage in therapeutic and cosmetic
applications.
[0194] Storage conditions for the compositions of the present
invention will depend on the electroprocessed materials and
substances therein. In embodiments involving proteins, for example,
it may be necessary or desirable to store the compositions at
temperatures below 0.degree. C., under vacuum, or in a lyophilized
condition. Other storage conditions can be used, for example, at
room temperature, in darkness, in vacuum or under reduced pressure,
under inert atmospheres, at refrigerator temperature, in aqueous or
other liquid solutions, or in powdered form. Persons of ordinary
skill in the art recognize appropriate storage conditions for the
materials and substances contained in the compositions and will be
able to select appropriate storage conditions.
[0195] The compositions of the present invention and formulations
comprising those compositions may be sterilized through
conventional means known to one of ordinary skill in the art. Such
means include but are not limited to filtration, radiation, and
heat. The compositions the present invention may also be combined
with bacteriostatic agents, such as thimerosal, to inhibit
bacterial growth.
[0196] Formulations comprising the compositions of the present
invention may be presented in unit-dose or multi-dose containers,
for example, sealed ampules and vials, and may be stored in a
freeze-dried (lyophilized) condition requiring only the addition of
the sterile liquid carrier, for example, water for injections,
immediately prior to use. Extemporaneous injection solutions and
suspensions may be prepared from sterile powders, granules and
tablets commonly used by one of ordinary skill in the art.
Preferred unit dosage formulations are those containing a dose or
unit, or an appropriate fraction thereof, of the administered
ingredient. It should be understood that in addition to the
ingredients particularly mentioned above, the formulations of the
present invention may include other agents commonly used by one of
ordinary skill in the art.
[0197] The compositions of the present invention may be packaged in
a variety of ways depending upon the method used for administering
the composition. Generally, an article for distribution includes a
container which contains the composition or a formulation
comprising the composition in an appropriate form. Suitable
containers are well-known to those skilled in the art and include
materials such as bottles (plastic and glass), sachets, ampules,
plastic bags, metal cylinders, and the like. The container may also
include a tamper-proof assemblage to prevent indiscreet access to
the contents of the package. In addition, the container has
deposited thereon a label which describes the contents of the
container. The label may also include appropriate warnings.
[0198] The present invention is further illustrated by the
following examples, which are not to be construed in any way as
imposing limitations upon the scope thereof. On the contrary, it is
to be clearly understood that resort can be had to various other
embodiments, modifications, and equivalents thereof, which, after
reading the description herein, can suggest themselves to those
skilled in the art without departing from the spirit of the present
invention.
Example 1
[0199] Fibroblast growth factor (FGF, obtained from Chemicon,
Temecula, Calif.) was dissolved in a solution of matrix material
comprised of type I collagen (80%), PGA (10%) and PLA (10%). The
percentages refer to the weight of the materials with respect to
one another. These materials were dissolved in HFIP at a final
concentration of 0.08 gm per ml. Sufficient FGF was added to 1 ml
of solution to provide an FGF concentration of 50 ng/ml of the
collagen/PGA/PLA electrospinning solution. The material was
electrospun into the shape of a cylinder onto the outer surface of
a grounded and spinning 16 gauge needle about 25-35 mm in length.
After application, the cylinder was sutured shut looping a suture
around the outside of the construct and pulling tight to seal the
ends. Alternatively, a hot forceps is used to pinch the ends
together and literally heat seal the ends shut. These methods
formed a hollow, enclosed construct. The construct was then
surgically implanted within the vastus lateralis muscle of a rat.
The construct was left in place for seven days and recovered for
inspection. FGF in the matrix accelerated muscle formation within
the electrospun matrix by promoting muscle formation within the
wall of the electrospun cylinder.
Example 2
[0200] Vascular endothelial growth factor (VEGF, obtained from
Chemicon, Temecula, Calif.) was dissolved in a solution of matrix
material comprised of type I collagen (80%), PGA (10%) and PLA
(10%) as described in EXAMPLE 1. These materials were dissolved in
HFIP at a final concentration of 0.08 gm per ml. Sufficient VEGF
was added to 1 ml of solution to provide a VEGF concentration of 50
ng/ml of the collagen/PGA/PLA electrospinning solution. The
material was electrospun to form a construct and implanted into a
rat muscle using the same procedures set forth in Example 1. VEGF
increased the density of functional capillaries that were present
throughout the construct. This was evidenced by the presence of
capillaries containing red blood cells (RBCs).
Example 3
[0201] Constructs of electroprocessed collagen and PGA:PLA
copolymer, with VEGF spun into the matrix were prepared using 80%
collagen and 20% PGA:PLA. The collagen and PGA:PLA were dissolved
in HFIP at a final combined concentration of 0.08 gm per ml.
Solutions were prepared in which different amounts of VEGF were
added to 1 ml of the solution of collagen and PGA:PLA copolymer.
Separate solutions were prepared containing 0 ng, 25 ng, 50 ng, and
100 ng each in 1 ml. Constructs were prepared for each solution by
electrospinning one ml. The constructs were cut into smaller
sections and placed in a phosphate buffer solution (PBS). Release
of VEGF into the PBS was measured as a function of time by the
ELISA method. The ELISA kit for VEGF was purchased from Chemicon
International (part number cyt214) and the directions provided in
the kit were followed to perform the ELISA. Samples were
centrifuged to remove particulate matter and stored at -20.degree.
C. prior to use.
[0202] An identical construct was subjected to crosslinking by
exposing it to glutaraldehyde vapor at room temperature and
subjected to an identical ELISA assay. A sample of the
electroprocessed construct was placed in a 100 mm tissue culture
dish. A 35 mm tissue culture dish containing 1 ml of 50%
glutaraldehyde was placed inside the 100 mm tissue culture dish.
The lid of the 100 mm tissue culture dish was replaced and the
sample was allowed to sit for 15 minutes at room temperature. The
sample was rinsed in sterile water or culture media. The amount of
VEGF (expressed in picograms per 1 mg of electrospun material) for
the non cross-linked and cross-linked samples was measured at
different times are presented in FIGS. 3 and 4, respectively.
[0203] In FIG. 3 and FIG. 4, the open diamonds represent release
from the fibers electrospun from the solution containing PGA:PLA
copolymer and collagen to which no VEGF was added. The open squares
represent release from fibers electrospun from the solution
containing PGA:PLA copolymer and collagen to which 25 ng of VEGF
were added. The open circles represent release from the fibers
electrospun from a solution containing PGA:PLA copolymer and
collagen to which 50 ng of VEGF were added. The open triangles
represent release from the fibers electrospun from a solution
containing PGA:PLA copolymer and collagen to which 100 ng of VEGF
were added. Results demonstrate not only that the matrix releases
VEGF in PBS but also that cross-linking with glutaraldehyde slows
release from the matrix.
Example 4
[0204] Polyethylene-co-vinyl acetate) (PEVA) was a gift from DuPont
(Elvax 40, 40 vinyl acetate). PEVA pellets were soaked in ethanol
for several days to remove antioxidants. Poly(lactic acid) (100 L
PLA) was a gift from by Alkermes, Inc. (Medisorb.RTM.) with a
number-average molecular weight, M.sub.n, of 205 KD and
polydispersity of 1.7. All solvents were analytical grade and were
used as received. Tris(hydroxymethyl)aminomethane hydrochloride
(Trizma.RTM. HCl) and trishydroxymethylaminomethane
(Trizma.RTM.-base) were supplied by Sigma and were used without
further purification to prepare buffer solutions of pH 7.35.
Tetracycline hydrochloride was also obtained from Sigma.
Actisite.RTM. periodontal fiber (0.5 rrim PEVA) containing 25 wt %
tetracycline hydrochloride was a gift from Alza Corporation (Palo
Alto, Calif.).
[0205] Electrospinning was carried out using 14% wt/v solutions of
100% PEVA, 100% PLA, or mixtures of the two in chloroform. The
mixtures used were 25% PEVA/75% PLA, 500%/50% of each, and 75%
PEVA/25% PLA, with percentages by weight Tetracycline
hydrochloride, which is insoluble in chloroform, was solubilized in
a small amount of methanol and added to the polymer solutions prior
to electrospinning. The resulting solutions were yellow but clear,
indicating homogeneous solubilization of both the polymers and
drug.
[0206] The electrospinning set-up consisted of a glass pipette
(held parallel to ground or angled at 45.degree. downward), 0.32 mm
diameter silver-coated copper wire (positive lead), a copper sheet
(ground electrode) ca. 30 cm from the pipette, and a Spellman
CZE100OR high voltage supply. A positive voltage (15 kV) was
applied through the copper wire to the polymer solution inside the
glass pipette. The solutions were delivered via syringe pumps to
control the mass flow rate, which ranged from 10-18 ml/h. More
conveniently, the solution can be held in a plastic syringe with
the high voltage supply connected to the metal syringe needle. The
solutions were delivered via syringe pumps to control the mass flow
rate, which ranged from 10-18 ml/h. The resulting electrically
charged fibers were collected on a rotating metal plate to produce
a sheet of non-woven fabric.
[0207] A 100 L PLA containing 5% tetracycline hydrochloride (by
weight) was electrospun from 14% W/V solution in chloroform, with a
mass flow rate of the polymer solution between 18-21 ml/h. PEVA
containing 5% tetracycline hydrochloride (expressed herein as by
weight of total polymer) was electrospun from 14% W/V solution with
a mass flow rate of 3 ml/h. Blends containing 5% tetracycline
hydrochloride and consisting of 25% PLA and 75% PEVA were
electrospun at mass flow rates of 13-18 ml/h. A 50/50 PLA/PEVA
blend with 5% tetracycline hydroxide was spun at a mass flow rate
of 10-13 ml/h. A 50/50 PLA/PEVA blend with 25% tetracycline
hydroxide (by weight of total polymer weight) was spun at a mass
flow rate of 15 ml/hr. A blend containing 75/25 PLA/PEVA with 5%
tetracycline hydroxide was spun with a mass flow rate of 17 ml/h.
The collected `fabric` was used for studying the release of
tetracycline hydrochloride.
[0208] For comparative purposes, cast films were made from
different compositions of PLA and PEVA. As with the fibers, films
were made of 25% PEVA/75% PLA, 50%/50% of each, and 75% PEVA/25%
PLA and 5% tetracycline hydrochloride was added to each. The
solutions in chloroform were cast onto glass petri dishes, left at
room temperature until the chloroform was evaporated, then dried at
25.degree. C. under vacuum for 3 hours. The release of tetracycline
hydrochloride from ACTISITE.RTM. (PEVA) periodontal fiber was also
compared.
[0209] Release of tetracycline hydrochloride was determined using
UV-VIS measurements carried out at Perkin-Elmer UV/VIS Lambda 40
Spectrophotometer. The molar extinction coefficient for
tetracycline hydrochloride in Tris buffer was found to be 15,800
from a linear Beer-Lambert plot of absorbance at 360 nm vs.
concentration. Release of tetracycline hydrochloride was determined
by placing a known mass of polymer and drug in tris buffer and
monitoring the absorbance at 360 nm as a function of time. The
buffer solution was changed if the released drug gave absorbance
higher than 2.0. Data are reported as the % tetracycline
hydrochloride released based upon the expected amount in the
samples from the feed composition. The morphology of the
electrospun samples were studied with JSM-820 Scanning electron
microscope (JEOL Ltd.).
[0210] The release profiles of tetracycline hydrochloride from
electrospun fibers and the cast films are shown in FIGS. 5 and 6.
In FIG. 5, the solid diamonds denote release from the fibers
electrospun from the solution in which the polymer was 50% EVA and
50% PLA and 5% tetracycline was added. The open circles denote
release from the fibers electrospun from the solution in which the
polymer was 50% EVA and 50% PLA and 25% tetracycline was added. The
open triangles denote release from the fibers electrospun from the
solution in which the polymer was 100% PLA and 5% tetracycline was
added. The solid squares denote release from the fibers electrospun
from the solution in which the polymer was 100% EVA and 5%
tetracycline was added.
[0211] In FIG. 6, the open diamonds denote release from the fibers
electrospun from the solution containing 100% EVA. The open squares
denote release from the ACTISITE.RTM. (PEVA) periodontal fiber. The
open triangles denote release from the film in which the polymer
was 50% PLA and 50% PEVA. The open circles denote release from the
film in which the polymer was 25% PLA and 75% PEVA. The solid
diamonds connected by a thick line denote release from the film
containing 100% PLA. The solid triangles denote release from the
film in which the polymer was 75% PLA and 25% PEVA. The solid
squares denote release from the fibers electrospun from the
solution containing 25% PLA and 75% PEVA. The solid diamonds
connected by a thin line denote release from film containing 100%
EVA.
[0212] Electrospun EVA showed a higher release rate than the mats
derived from PLA/EVA (50/50) or pure PLA. Electrospun PEVA released
65% of its drug content within 100 hours, whereas the electrospun
50/50 mixture of PEVA and PLA released about 40% over the same time
period. Mats of PLA fibers with no PEVA exhibit some instantaneous
release, with negligible release over 50 hours. The 50:50 sample
with 25 wt % tetracycline hydrochloride releases the drug more
rapidly than the 5% sample, although the % released of the former
approaches that of the latter after 150 hrs.
[0213] FIG. 7 shows release profiles of three electrospun PEVA
samples, two from the same batch of mat and another from a
different preparation under identical conditions. The release
amounts of each sample are denoted by solid diamonds, solid
squares, and open triangles, respectively. The profiles are quite
similar indicating very good reproducibility. In general, the
initial rate of release of all formulations including ACTISITE.RTM.
(denoted as Alza) is high during the first 10-12 hours, most likely
due to release of drug sequestered on the sample surfaces. The
total percent released from the cast films (FIG. 6) were lower than
that of the electrospun mats, as would be expected due to the much
lower surface area of the former. The PLA/EVA 75/25 film released
30% of its tetracycline hydrochloride in 120 hrs, whereas the film
of 50/50 PLA/EVA showed a slightly lower percent of release (25%)
in the same period of time. Release from the PLA film was much
lower, only 6% released in 120 hrs, whereas the PEVA film showed 8%
release over the same period.
Example 5
[0214] A mixture of cultured insulin secreting cells is seeded into
an electroprocessed collagen matrix to form an electroprocessed
collagen-containing tissue. The electroprocessed matrix containing
the insulin secreting cells is implanted into a diabetic recipient
in need of insulin. This electroprocessed collagen or
fibrin-containing tissue optionally contains a vessel. The matrix
is implanted into the retroperitoneal space and the vessel is
anastomosed into the hepatic portal circulation. Insulin is
released from the insulin-containing cell and transmitted to the
circulation.
[0215] The electroprocessed matrix containing the insulin secreting
cells is optionally supplemented with cells that synthesize and
secrete glucagon, somatostatin, pancreatic polypeptide, or
combinations thereof, in order to mimic the hormonal complement of
the pancreatic islet.
[0216] Optionally, heterologous cells, (for example, engineered
bacteria or cells from a conspecific donor) are placed in a matrix
with a pore size that will allows diffusion of nutrients to the
cells but does not allow or inhibits or delays the detection of the
cells by the recipient's immune system.
Example 6
[0217] Keratinocytes are harvested from a healthy site of a patient
suffering from a chronic wound. The cells are grown in culture and
transfected by electroporation to express VEGF. Next, the
transfected cells are mixed or prepared in an electrospun collagen
matrix. Antisense oligonucleotide for matrix metalloproteinases
(MMPs) are also spun into the matrix. The matrix is topically
applied to the surface of the wound. The cells near and in the
implant take up the antisense sequences, express their transfected
gene sequences and MMP production is reduced. In other applications
the cells may be genetically engineered to secrete VEGF, thereby
promoting healing. Release of the antisense oligonucleotides
suppress expression of MMPs, which are typically overexpressed in a
chronic wound. Thus the wound site is repaired with an implant that
simultaneously promotes natural healing responses. Optionally, the
matrix is comprised of fibrin or a mix of fibrin and collagen. The
fibrin assists in cessation of bleeding and promotes healing.
Example 7
[0218] Osteoblasts from a patient with a bone injury are cultured
and incorporated into an electrospun matrix comprising type I
collagen. The matrix is formed in the shape of a cavity or defect
at the injury site. Bone growth factor (BGF), bone morphogenic
protein (BMP) or sequences of genes encoding for these proteins,
are electrospun into the matrix are optionally incorporated into
the electrospun matrix. The matrix assists in growth of new bone,
and the BGF or BMP in the matrix promotes bone growth.
[0219] Optionally, the collagen used is produced in vitro by
genetically engineered cells that express a collagen polymer with
more P-15 sites than in normal collagen. The excess of P-15 sites
promotes osteoblasts to produce and secretes hydroxyapatite and
further aid bone growth.
[0220] Optionally, the matrix is further electroprocessed with
polypyrroles, which are electrically active materials. Electrodes
are attached to each end of the implanted matrix. Charged
electrodes are later applied to the surface over the electrodes to
create a small electric current across the implant to further
facilitate healing of the bone injury. In another embodiment
piezoelectric elements may be electrospun into the matrix to
produce electric discharges that promote healing.
Example 8
[0221] In another example, similar to that described for skeletal
muscle a cardiac patch is prepared. A sheet of electroprocessed
material is prepared with aligned filaments of collagen. The sheet
is folded into a pleated sheet in the desired shape and or rolled
into a cylinder. A second construct is electrospun in the desired
shape, for example a rectangle. The pleated sheet that mimics the
cellular layers of the intact heart is inserted into the
electroprocessed rectangular form. The construct is filled with
cells, sutured shut and placed in a bioreactor or directly in situ.
By aligning the fibrils of the pleated electrospun sheet of
material in parallel with the long axis of the outer rectangular
form, a cardiac, muscle-like construct is obtained. Native cardiac
tissue is composed of layers of cells arrayed along a common axis
with adjacent cell layers slightly off axis with the overlaying and
underlying layers. This structure is more precisely mimicked by the
methods described below in which a matrix is prepared and cells are
directly electroprocessed, dribbled or sprayed onto the matrix as
it is prepared. Cells in contact with the fibrils that are arrayed
along the long axis of the sheet spread in parallel with the
underlying fibrils of the sheet, forming a muscle construct of
cells arrayed and layered in an in vivo-like pattern of
organization. The construct can be directly implanted or placed
within a RCCS bioreactor. Rates of rotation to maintain this type
of construct in suspension range from 4-20 rpm, depending upon the
mass of the tissue and the specific materials used to fabricate the
outer cylinder. Variations of this design include the addition of
angiogenic factors in the matrix, gene sequences, and agents to
suppress inflammation and/or rejection. Other cell types may be
added to the construct, for example microvascular endothelial
cells, to accelerate the formation of a capillary system within the
construct. Other variations in this design principle can be used.
For example, cells may be electroprocessed into the matrix as it is
deposited on the ground target. By varying the pitch of the fibers
during spinning and spraying, dribbling or electroprocessing cells
onto the fibers as they are deposited very precisely controls the
positioning of the cells within the construct.
[0222] All patents, publications and abstracts cited above are
incorporated herein by reference in their entirety. It should be
understood that the foregoing relates only to preferred embodiments
of the present invention and that numerous modifications or
alterations can be made therein without departing from the spirit
and the scope of the present invention as defined in the following
claims.
* * * * *